EP2373635A1 - Benzothiazolone derivative - Google Patents

Abstract

The invention relates to compounds of the formula I, where R¹, R², R³, R^3', R⁴, R^4', E, E', E" and E"' have the meanings given in claim 1, being inhibitors of tyrosine kinases, in particular met kinase, and can be used for treating tumors, among other uses.

Description

 Benzothiazolonderivate

BACKGROUND OF THE INVENTION

5

The invention was based on the object, new compounds with valuable

Find properties, especially those that can be used for the production of medicines.

The present invention relates to compounds and the use of

Compounds in which the inhibition, regulation and / or modulation of the signal transduction of kinases, in particular the tyrosine kinases and / or serine / threonine kinases, also pharmaceutical compositions containing these compounds, as well as the use of the compounds for the treatment of kinase-related Diseases.

More particularly, the present invention relates to compounds and to the use of compounds in which the inhibition, regulation and / or modulation of Met-kinase signal transduction play a role.

One of the major mechanisms by which cell regulation is effected is through the transduction of extracellular signals across the membrane, which in turn modulate biochemical pathways in the cell. Protein phosphorylation is a process by which intracellular signals are propagated from molecule to molecule, ultimately resulting in a cellular response.

^OKJ These signal transduction cascades are highly regulated and often overlap, as evidenced by the presence of many protein kinases as well as phosphatases. Phosphorylation of proteins occurs predominantly on serine, threonine or tyrosine residues, and protein kinases therefore become weaker

35 their specificity of Phosporylierungsortes, ie the serine / threonine kinases and tyrosine kinases classified. Because phosphorylation is so far is widespread process in cells, and since cell phenotypes are largely influenced by the activity of these pathways, it is presently believed that a number of disease states and / or diseases are due to either aberrant activation or functional mutations in the molecular components of kinase cascades. Consequently, considerable attention has been paid to the characterization of these proteins and compounds capable of modulating their activity (For review, see: Weinstein-Oppenheimer et al., Pharm. &. Therap., 2000, 88, 229-279).

The role of receptor tyrosine kinase Met in human oncogenesis, as well as the possibility of inhibiting hepatocyte growth factor (HGF) -dependent Met activation, is described by S. Berthou et al. in Oncogene, Vol. 23, No. 31, pages 5387-5393 (2004). The inhibitor SU11274 described there, a pyrrole-indoline compound, is potentially suitable for combating cancer.

Another met kinase inhibitor for cancer therapy is described by J. G. Christensen et al. in Cancer Res. 2003, 63 (21), 7345-55. Another anti-cancer tyrosine kinase inhibitor is reported by H. Hov et al. in Clinical Cancer Research Vol. 10, 6686-6694 (2004). The

Compound PHA-665752, an indole derivative, is active against the HGF receptor c-

Met directed. It is also reported there that HGF and Met significantly contribute to the malignant process of various types of cancers, e.g. multiple myeloma.

The synthesis of small compounds that specifically inhibit, regulate and / or modulate the signal transduction of the tyrosine kinases and / or serine / threonine kinases, particularly the Met kinase, is therefore desirable and an object of the present invention. It has been found that the compounds according to the invention and their salts possess very valuable pharmacological properties with good compatibility.

In particular, the present invention relates to compounds of formula I which inhibit, regulate and / or modulate Met-kinase signal transduction, compositions containing these compounds, and methods for their use in the treatment of met-kinase-related diseases and conditions, such as angiogenesis, Cancer, tumorigenesis,

Growth and dissemination, atherosclerosis, eye diseases such as age-related macular degeneration, choroidal neovascularization and diabetic retinopathy, inflammatory diseases, arthritis, thrombosis, fibrosis, glomerulonephritis, neurodegeneration, psoriasis, restenosis,

Wound healing, graft rejection, metabolic and immune system disorders, including autoimmune diseases, cirrhosis, diabetes and blood vessel diseases, as well as instability and permeability

(Permeability) and the like in mammals.

Solid tumors, especially fast growing tumors, can be treated with Met kinase inhibitors. These solid tumors include monocytic leukemia, brain, urogenital, lymphatic, gastric, laryngeal and lung carcinomas, including lung adenocarcinoma and small cell lung carcinoma.

The present invention is directed to methods for the regulation, modulation or inhibition of Met kinase for the prevention and / or

Treatment of Disorders Associated with Unregulated or Disturbed Met Kinase Activity. In particular, the compounds of the formula I can also be used in the treatment of certain forms of cancer.

Furthermore, the compounds of Formula I can be used to be additive or synergistic in certain existing cancer chemotherapies

To provide effects, and / or can be used to the - A -

Restore the efficacy of certain existing cancer chemotherapies and radiation.

Furthermore, the compounds of formula I for isolation and to

Examination of the activity or expression of Met kinase can be used. In addition, they are particularly suitable for use in diagnostic procedures for diseases associated with unregulated or disturbed met kinase activity.

It can be shown that the compounds according to the invention have an in vivo antiproliferative action in a xenograft tumor model. The compounds of the invention are administered to a patient with a hyperproliferative disorder, e.g. To inhibit tumor growth, to reduce inflammation associated with lymphoproliferative disease, to inhibit graft rejection or neurological damage due to

Tissue repair, etc. The present compounds are useful for prophylactic or therapeutic purposes. As used herein, the

The term "treating" is used to refer to both the prevention of disease and the treatment of pre-existing conditions Prevention of proliferation by administration of the compounds of the present invention prevents development of the apparent disease, e.g., to prevent tumor growth, prevent metastatic growth which achieves reduction of cardiovascular surgery-associated restenosis, etc. Alternatively, the compounds are used to treat persistent diseases by stabilizing or ameliorating the clinical symptoms of the patient.

The host or patient may be of any mammalian species, e.g. B. one

Primate species, especially humans; Rodents, including mice,

Rats and hamsters; Rabbits; Horses, cattle, dogs, cats etc.

Animal models are of interest for experimental studies, wherein they provide a model for treating a human disease.

The susceptibility of a particular cell to treatment with the compounds of the invention can be determined by testing in vitro. Typically, a culture of the cell is combined with a compound of the invention at various concentrations for a period of time sufficient to allow the active agents to induce cell death or inhibit migration, usually between about one hour and one week. For testing in vitro, cultured cells from a biopsy sample can be used. The viable cells remaining after treatment are then counted. The dose will vary depending on the specific compound used, the specific disease, the patient status, etc. Typically, a therapeutic dose will be sufficient to substantially reduce the undesirable cell population in the target tissue while increasing the viability of the patient

Patient is maintained. Treatment is generally continued until there is a significant reduction, e.g. At least about 50%

Reduction of cell load and can be continued until essentially no more unwanted cells are detected in the body.

To identify a signal transduction pathway and to detect interactions between different signal transduction pathways, appropriate models or model systems have been developed by various scientists, e.g. Cell culture models (e.g., Khwaja et al., EMBO, 1997, 16, 2783-93) and models of transgenic animals (e.g., White et al.

Oncogene, 2001, 20, 7064-7072). To determine particular levels in the signal transduction cascade, interacting compounds can be used to modulate the signal (e.g., Stephens et al., Biochemical J., et al.

2000, 351, 95-105). The compounds according to the invention can also be described as

Reagents for Testing Kinase - Dependent Signal Transduction Pathways in Animals and / or cell culture models or in the clinical diseases mentioned in this application.

The measurement of kinase activity is a technique well known to those skilled in the art. Generic Assay Systems for Determining Kinase Activity with Substrates, e.g. Histone (eg Alessi et al., FEBS Lett. 1996, 399, 3, pp. 333-338) or the myelin basic protein are described in the literature (eg Campos-Gonzalez, R. and Glenney, Jr., JR 1992, J. Biol. Chem. 267, page 14535).

Various assay systems are available for the identification of kinase inhibitors. In the Scintillation Proximity Assay (Sorg et al., J. of Biomolecular Screening, 2002, 7, 11-19) and the FlashPlate assay, the radioactive phosphorylation of a protein or peptide as a substrate is measured with γATP. In the presence of an inhibitory compound, no or a reduced radioactive signal is detectable. Further, homogenous time-resolved fluorescence resonance energy transfer (HTR-FRET) and fluorescence polarization (FP) technologies are useful as assay methods (SiIIs et al., J. of Biomolecular Screening, 2002, 191-214).

Other non-radioactive ELISA assay methods use specific phospho-antibodies (Phospho-AK). The phospho-AK binds only the phosphorylated substrate. This binding is detectable with a second peroxidase-conjugated anti-sheep antibody by chemiluminescence

(Ross et al., 2002, Biochem J.).

There are many diseases associated with deregulation of cell proliferation and cell death (apoptosis). The ailments of interest include, but are not limited to, the following conditions. The compounds of the invention are useful in the treatment of a variety of conditions involving proliferation and / or migration smooth muscle cells and / or inflammatory cells in the intimal layer of a vessel is present, resulting in limited blood flow to this vessel, z. In neointimal occlusive lesions. Occlusive transplant vascular diseases of interest include atherosclerosis, coronary vascular disease after transplantation, vein graft stenosis, peri-anastomotic prosthetic restenosis, restenosis after angioplasty or stent placement, and the like.

PRIOR ART TO MET KINASE INHIBITORS

Thiadiazinones are disclosed in WO 03/037349

4,5-dihydropyrazoles for combating cancer are known from WO 03/079973 A2.

Quinoline derivatives are described in EP 1 411 046 A1. Pyrrole-indoline derivatives are disclosed in WO 02/096361 A2. 1-acyldihydropyrazole derivatives are known from WO 2007/019933.

Pyridazinone derivatives are described in WO 2006/010668.

Substituted 5-phenyl-3,6-dihydro-2-oxo-6 / - / - [1, 3,4] thiadiazines are known from WO 2006/010285.

3,6-Dihydro-2-oxo-6H- [1, 3,4-] thiadiazine derivatives are described in WO 2006/010286.

In addition, other met kinase inhibitors are known from WO 2005/004607, WO 2005/030140, WO 2006/014325, WO 2006/021881 and WO 2006/021881.

SUMMARY OF THE INVENTION

The invention relates to compounds of the formula I. wherein

E, E ', E ", E" ¹ each independently of one another C or N,

R ¹ , R ^{2 are} each independently H or A, R ¹ and R ² together also (CH ₂ ) _P , where 1 or 2 CH ₂ group (s) may be replaced by O and / or NH,

R ³ H, Ar, (CH ₂ ) nCONH _2l (CH ₂ ) _n CONHA, (CH ₂ ) _n CONAA \ A, COA, OH,

OA, CONH (CH ₂ ) _m NH ₂ , CONH (CH ₂ ) _m NHA, CONH (CH ₂ ) _m NAA ', CO (CH ₂ ) _m NH ₂ , CO (CH ₂ ) _m NHA, CO (CH ₂ ) _m NAA ', CO (CH ₂ ) _m Het, CH (OH) A, CN, (CH ₂ ) _n Het, Hal, CONH (CH ₂ ) _m NA-COOA, SO ₂ A,

NH (CH ₂ ) _m NH ₂ , NH (CH ₂ ) _m NHA, NH (CH ₂ ) _m NAA ', (CH ₂ ) _n COOH, (CH ₂ ) _n COOA, O (CH ₂ ) _m NH ₂ , O (CH ₂ ) _m NHA, O (CH ₂ ) _m NAA ', OHet, N = CH-NAA ¹ , N = CH-NHA, N = CH-NH ₂ , O (CH ₂ ) _m Het, N (R ⁶ ) ₂ , NR ⁶ COA, NR ⁶ SO ₂ A ₁ SO ₂ N (R ⁶ ) ₂ , [C (R ⁶ ) ₂ ] _n N (R ⁶ ) ₂ ,

S [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂ , S [C (R ⁶ ) ₂ ] _n Het, -NR ⁶ [C (R ⁶ ) ₂ ] _n Het, NHCON (R ⁶ ) ₂ , NHCONH [C (R ⁶ ) ₂ ] _p N (R ⁶ ) _{2 l} NHCONH [C (R ⁶ ) ₂ ] _n Het, NHCO [C (R ⁶ ) ₂ ] _P-

N ( COHet, O [C (R ⁶ ) ₂ ] _P NR ⁶ COZ, O [C (R ⁶ ) ₂ ] pNR ² COHet ¹ ,

O [C (R ⁶ ) ₂ ] _n Cyc [C (R ⁶ ) ₂ ] _n N (R ⁶ ) ₂ ,

O [C (R ⁶ ) ₂ ] _n Cyc [C (R ⁶ ) ₂ ] _n OR ⁶ , O [C (R ⁶ ) ₂ ] _n Cyc [C (R ⁶ ) ₂ ] _n Het ¹ , CH ₂ - ( CH ₂ ) ,,

\ / O [C (R ⁶ ) ₂ ] _n -C- [C (R ⁶ ) ₂ ] _n N (R ⁶ ) ₂ _

CH ₂ - (CH ₂ X,

\ / O [C (R6) _{2] n} -C- [C (R ⁶⁾ _{2] n} OR ^β _i CH ₂ - (CH ₂ ),

\ /

0 [C (Re) ₂ I _n -C- [C (Re) ₂ I _n HeI ₁

O [C (R ⁶ ) ₂ ] nCR ⁶ (NR ⁶ ) ₂ COOR ⁶ , 5 O [C (R ⁶ ) ₂ ] n NR ⁶ CO [C (R ⁶ ) ₂ ] n NR ⁶ COA, O [C (R ⁶ ) ₂ ] _P NR ⁶ COOA,

O [C (R ⁶ ) ₂ ] _n CO-NR ⁶ -A,

O [C (R ⁶ ) ₂ ] _n CO-NR ⁶ - [C (R ⁶ ) ₂ ] n Het ¹ , O [C (R ⁶ ) ₂ ] _n CONH ₂ ,

O [C (R ⁶ ) ₂ ] nCONHA, O [C (R ⁶ ) ₂ ] _n CONA ₂ ,

10 O [C (R ⁶ ) ₂ ] nCO-NR ⁶ - [C (R ² ) ₂ ] _n N (R ⁶ ) 2 or OCOA,

Z CR ⁶ (NR ⁶ ) ₂ CR ⁶ (OR ⁶ ) A,

R ^{3 '} H or Hal,

R ^{4 is} Het ¹ , NHCOOR ⁵ , NHCONHR ⁵ , NHCOCONHR ⁵ , NO ₂ or

NHCOA,

R ^{4 'is} H or Hal,

R ⁴ and R ^{4 '} together also NHCONH,

R ⁵ A, (CH ₂ ) _m NH ₂ , (CH ₂ ) _m NHA, (CH ₂ ) _m NAA 'or (CH ₂ ) _m Het,

Ar is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH,

²⁰ OA, N (R ⁶ ) ₂ , SR ⁶ , NO ₂ , CN ₁ COOR ⁶ , CON (R ⁶ ) ₂ , NR ⁶ COA,

NR ⁶ SO ₂ A, SO ₂ N (R ⁶ J ₂ , S (O) _1n A, CO-Het ¹ , [C (R ⁶ ) ₂ ] _n N (R ⁶ ) ₂ ,

[C (R ⁶ ) ₂ ] _n Het ¹ , O [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂ , O [C (R ⁶ ) ₂ ] _n Het ¹ , NHCOOA,

NHCON (R ⁶ ) ₂ , NHCOO [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂ , NHCOO [C (R ⁶ ) ₂ ] _n Het ¹ , 25 NHCONH [C (R ⁶ ) ₂ ] _P N ( R ³ ) ₂ , NHCONH [C (R ⁶ ) ₂ ] _n Het ¹ ,

OCONH [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂ and / or OCONH [C (R ⁶ ) ₂ ] _n Het ^{1 is} substituted phenyl, naphthyl or biphenyl, Het is a mono- or binuclear saturated, unsaturated or aromatic heterocycle with 1 to 4 N, O and / or S atoms, or which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR ⁶ , N (R ⁶ ) ₂ , NO ₂ , CN, COOR ⁶ , CON (R ⁶ ) ₂ , NR ³ COA, NR ⁶ SO ₂ A, SO ₂ N (R ⁶ ) ₂ , S (O) _n A, NHCOOA ₁ NHCON (R ⁶ ) ₂ , CHO, COA, = S, = NH, = NA and / or = O (carbonyl oxygen) may be substituted ³⁵ , Het ^{1 is} a mononuclear aromatic heterocycle having 1 to 4 N, O and / or S atoms which is unsubstituted or mono-, di- or trisubstituted, each independently of one another, may be substituted by R ³ , R ^{6 is} H or A. .

A, A ^{1 are} each independently of one another unbranched or branched alkyl having 1-10 C atoms, wherein 1-7 H atoms may be replaced by F, Cl and / or Br, and / or wherein one or two Ch ^ groups O, S, SO, SO ₂ and / or CH = CH groups may be replaced, or cyclic alkyl having 3-7 C atoms,

Cyc cycloalkylene having 3-7 C atoms,

Hal is F, Cl, Br or I, m is 1, 2, 3 or 4, n is 0, 1, 2, 3 or 4, p is 1, 2, 3, 4 or 5, q is 1, 2, 3, 4 or 5 and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios,

Compounds of the formula I are also understood as meaning the hydrates and solvates of these compounds, and also pharmaceutically usable derivatives. The invention also relates to the optically active forms

(Stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. Solvates of the compounds are understood to mean additions of inert solvent molecules to the compounds, which due to their mutual

Train attraction. Solvates are e.g. Mono- or dihydrate or

Alcoholates. Pharmaceutically usable derivatives are understood as meaning, for example, the salts of the compounds according to the invention and also what are known as prodrug compounds.

Under prodrug derivatives is understood with z. As alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which are rapidly cleaved in the organism to the active compounds of the invention.

These include biodegradable polymer derivatives of the compounds of the invention, as z. In Int. J. Pharm. 115, 61-67 (1995).

The term "effective amount" means the amount of a drug or pharmaceutical agent which elicits a biological or medical response in a tissue, system, animal or human, e.g. sought or desired by a researcher or physician.

In addition, the term "therapeutically effective amount" means one

Amount that, as compared to a corresponding subject that has not received this amount, results in: improved healing, healing, prevention or elimination of one

Illness, a medical condition, a medical condition, a disease, a disorder or side effects or even those

Reduction of the progression of a disease, a disease or a disease

Disorder.

The term "therapeutically effective amount" also includes the amounts effective to increase normal physiological function.

The invention also provides the use of mixtures of the compounds of formula I, e.g. Mixtures of two diastereomers, e.g. in the

Ratio 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1:10, 1: 100 or 1: 1000.

Particularly preferred are mixtures of stereoisomeric

Links. The invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I according to claims 1-11 and their pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers, characterized in that a) a Compound of formula II

5 in which E, E ', E ", E"', R and R have the meanings given in claim 1,

with a compound of the formula IM 0

wherein R ¹ , R ² , R ⁴ and R ^{4 have} the meanings given in claim 1 and Q is Cl, Br, I or a free or reactively functionally modified OH group,

converts, 5.,. and / or converting a base or acid of the formula I into one of its salts. Above and below, the radicals R ¹ , R ² , R ³ , R ^{3 '} , R ⁴ , R ^4' , E ₁ E ", E" and E '"have the meanings given for the formula I, unless expressly stated another is indicated.

Abbreviations:

TFA trifluoroacetic acid DCM dichloromethane

A, A ', each independently, alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1, 1, 2 or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-,

2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methyl-propyl, 1-ethyl-2-methylpropyl, 1, 1, 2 or 1, 2,2-trimethylpropyl, more preferably, for example Trifluoromethyl.

A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl , Pentafluoroethyl or 1,1,1-trifluoroethyl.

Cyclic alkyl (cycloalkyl) is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

Ar means e.g. Phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p- tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p- (N-methylamino) -phenyl, o-, m- or p- (N-

Methylaminocarbonyl) -phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-

Methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonyl- phenyl, o-, m- or p- (N, N-dimethylamino) -phenyl, o-, m- or p- (N, N-dimethylaminocarbonyl) -phenyl, o-, m- or p- (N -Ethylamino) -phenyl, o-, m- or p- (N, N-diethylamino) -phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p- (methylsulfonamido) -phenyl, o-, m- or p- (methylsulfonyl) -phenyl, o-, m- or p-methylsulfanylphenyl, o-, m- or p- Cyanophenyl, o-, m- or p-carboxyphenyl, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-aminosulfonylphenyl, more preferably 2,3-, 2,4-, 2,5-, 2 , 6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3- , 2,4-, 2,5-, 2,6-, 3,4- or 3,5-di-bromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl , 3-Nitro-4-chlorophenyl, 3-amino-4-chloro, 2-amino-3-chloro, 2-amino-4-chloro, 2-amino-5-chloro or 2-amino-6 -chlorophenyl, 2-nitro-4-N, N-dimethylamino or 3-nitro-4-N, N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-, 2, 3,6-, 2,4,6- or 3,4,5- Trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-Difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, 3

Fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.

Ar is particularly preferably mono-, di- or trisubstituted by Hal and / or CN substituted phenyl.

Het, irrespective of further substitutions, e.g. 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, A- or 5-pyrazolyl, 2 -, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2 -, A-, 5- or 6-pyrimidinyl, more preferably 1, 2,3-triazole-1, -A- or -5-yl, 1, 2,4-triazole-1, -3 or 5 -yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or -5-yl, 1, 2,4-

Oxadiazol-3 or -5-yl, 1, 3,4-thiadiazol-2 or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1, 2,3-thiadiazole 4- or 5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-,

2-, 3-, A-, 5-, 6- or 7-indolyl, A- or 5-isoindolyl, indazolyl, 1-, 2-, A- or 5-benzimidazolyl, 1-, 3-, A-, 5-, 6- or 7-benzopyrazolyl, 2-, A-, 5-, 6- or 7-benzoxazolyl, 3-, A-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7- benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, A-, 5-, 6- or 7-benz- 2,1,3-oxadiazolyl, 2-, 3-, A-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8- isoquinolyl, 3-, A-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-

Quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo [1,4] oxazinyl, more preferably 1,3-benzodioxol-5-yl, 1, 4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4 or 5-yl, 2,1,3-benzoxadiazol-5-yl or dibenzofuranyl.

The heterocyclic radicals may also be partially or completely hydrogenated.

Regardless of other substitutions Het can thus z. B. also represent 2,3-dihydro-2-, -3-, -A- or -5-furyl, 2,5-dihydro-2-, -3-, -A- or 5-furyl,

Tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or 3-thienyl, 2,3-dihydro-1-, 2-, -3-, -A- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -A- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-

Dihydro-1-, -2-, -3-, -A- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl,

1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-i, -2-, -3-, -A-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1 , 3-dioxane-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -A- or -5-pyrimidinyl, 1 -, 2- or 3-piperazinyl, 1, 2,3,4-tetrahydro-1, -2, -3, -4, -5-, -6, -7- or -8-quinolyl , I ^ .S ^ -Tetrahydro-i -. ^ -.- S-, -A-, -5-, -6-, -7- or -8- isoquinolyl, 2-, 3-, 5-, 6 -, 7- or 8-3,4-dihydro-2H-benzo [1,4] oxazinyl, more preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3 , 4- (difluoromethylenedioxy) -phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3- (2-oxomethylenedioxy) -phenyl or also 3,4-dihydro-2H-1,5-benzodioxepin -6- or -7-yl, furthermore preferably 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 3,4-dihydro-

2-oxo-1H-quinazolinyl, 2,3-dihydrobenzoxazolyl, 2-oxo-2,3-dihydrobenzoxazolyl, 2,3-dihydrobenzimidazolyl, 1,3-dihydroindole, 2-oxo-1,3 dihydroindole or 2-oxo-2,3-dihydrobenzimidazolyl. In a further embodiment, Het preferably denotes a mono- or binuclear saturated, unsaturated or aromatic heterocycle having 1 to 3 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by A and / or = O (carbonyl oxygen) may be substituted.

Het is particularly preferably piperidin-yl, pyrrolidin-yl, morpholin-4-yl, piperazin-yl, 1, 3-oxazolidin-3-yl, imidazolidinyl, oxazolyl, oxadiazolyl, thiazolyl, thienyl, furanyl or pyridyl, where the radicals also may be substituted once or twice by A and / or = O (carbonyl oxygen).

Het ¹ means, notwithstanding further substitutions, for example 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3- , 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or

5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-

Pyrimidinyl, furthermore preferably 1, 2,3-triazole-1, -4- or -5-yl, 1, 2,4-triazole

1-, 3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or -5-yl, 1, 2,4-oxadiazol-3 or -5-yl, 1, 3,4-thiadiazol-2 or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1, 2,3-thiadiazol-4 or -5-yl, 3 or 4-pyridazinyl or pyrazinyl. Het ¹ particularly preferably denotes 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1, 2,3-triazole-1, -4- or -5-yl, 1, 2,4-triazole-1, -3 - or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or -5-yl, 1, 2,4-oxadiazol-3 or -5-yl, 1, 3,4 Thiadiazole-2 or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1, 2,3-thiadiazol-4 or -5-yl, 3- or 4-pyridazinyl or pyrazinyl, which is unsubstituted or mono- or disubstituted by A, O (CH ₂₎ m NH _2, O (CH ₂₎ MNHA, 0 (CH _{2) O1} NAA ^1, Het, OHet, N = CH-NAA ^1, N = CH -NHA, N = CH-NH ₂ and / or O (CH ₂ ) _m Het are substituted. E is C or N; E ¹ , E ", E '" are preferably C. R ⁶ is preferably H, methyl, ethyl, propyl, isopropyl, butyl or tert-butyl.

Hal preferably denotes F, Cl or Br ₁ but also I, particularly preferably F or Cl.

For the entire invention, all residues that occur multiple times may be the same or different, i. are independent of each other. The compounds of the formula I can possess one or more chiral centers and therefore occur in different stereoisomeric forms. Formula I encompasses all these forms.

Accordingly, the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings given above. Some preferred groups of compounds may be through the following

Partial formulas Ia to Ig are expressed which correspond to the formula I and wherein the unspecified radicals corresponding to those given in the formula I.

Meaning, in which, however

in Ia A, A 'are each independently of one another unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and / or Cl;

in Ib Het a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 3 N, O and / or S atoms, which is unsubstituted or mono- or disubstituted by A and / or COOR ⁶ may be substituted; in Ic Het piperidinyl, pyrrolidin-yl, morpholin-4-yl, piperazin-yl, 1, 3

Oxazolidin-3-yl, imidazolidinyl, oxazolyl, oxadiazolyl, thiazolyl, thienyl, furanyl or pyridyl, wherein the radicals are also one or two times by A and / or

COOR ⁶ can be substituted means;

in Id E, E ¹ , E ", E ^IM C, mean;

in Ie R ¹ , R ^{2 is} H;

in If R ■ 3 ^J A, COA, (CH ₂ ) _n Het, Hal, O (CH ₂ ) _m NAA 'or O (CH ₂ ) _m Het;

in Ig R ^{3 is} H;

in Ih R ^{4 is} Het ¹ , NHCOOR ⁵ or NO ₂ ;

in Ii R ^{4 '} H means;

in Ij R ^{5 is} (CH ₂ ) _m Het;

in Ik R ^{6 is} H, methyl, ethyl, propyl, isopropyl, butyl or tert-butyl;

in Il Het ¹ 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-

, 2, 4 or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5- -

Thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl,

2-, 4-, 5- or 6-pyrimidinyl, 1, 2,3-triazoM-, -4- or -5-yl, 1, 2,4-triazole-1 -, -3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or -5-yl, 1, 2,4-oxadiazole 3- or -5-yl, 1, 3,4-thiadiazol-2 or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1, 2,3-thiadiazole-4 or -5-yl, 3- or 4-pyridazinyl or pyrazinyl which is unsubstituted or mono- or disubstituted by A, O (CH ₂ ) m NH ₂ , O (CH ₂ ) _m NHA, O (CH ₂ ) _m NAA \ Het , OHet, N = CH-NAA ¹ ,

N = CH-NHA, N = CH-NH ₂ and / or O (CH ₂ ) _m Het are substituted;

in E, E ', E ", E" ¹ C, R, RH,

R ³ A, COA, (CH ₂ ) _n Het, Hal, O (CH ₂ ) _m NAA 'or O (CH ₂ ) _m Het,

R ^{3 '} H,

R ^{4 is} Het ¹ , NHCOOR ⁵ or NO ₂ ,

R ^{4 '} H, R ⁵ (CH ₂ ) _m Het,

Ar mono-, di- or trisubstituted by Hal and / or CN substituted phenyl,

Het piperidinyl, pyrrolidin-yl, morpholin-4-yl, piperazin-yl, 1,3-oxazolidin-3-yl, imidazolidinyl, oxazolyl, oxadiazolyl,

Thiazolyl, thienyl, furanyl or pyridyl, where the radicals can also be monosubstituted or disubstituted by A and / or COOR ⁶ , Het ¹ 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3 -Pyrrolyl, 1-

, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5- Thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl,

2-, 4-, 5- or 6-pyrimidinyl, 1, 2,3-triazoM-, -4- or -5-yl,

1, 2,4-triazoM, -3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-

Oxadiazol-4 or -5-yl, 1, 2,4-oxadiazol-3 or -5-yl, 1, 3,4-thiadiazol-2 or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1, 2,3-thiadiazol-4 or -5-yl, 3 or 4-pyidazinyl or pyrazinyl which is unsubstituted or monosubstituted or disubstituted by A, O (CH ₂ ViNH ₂ , O (CH ₂ ) _m NHA, O (CH ₂ ) _m NAA \ Het, OHet, N = CH-NAA ¹ .

N = CH-NHA, N = CH-NH ₂ and / or O (CH ₂ ) _m Het are substituted,

R ^{6 is} H, methyl, ethyl, propyl, isopropyl, butyl or tert-butyl, A ₁ A ^{1 are} each independently of one another unbranched or branched alkyl having 1-10 C atoms, wherein 1-7 H atoms by F and / or Cl can be replaced, Hal denotes F, Cl, Br or I, m is 1, 2, 3 or 4;

and their pharmaceutically usable derivatives, salts, solvates,

TTaauuttoommeerree uunncd stereoisomers, including mixtures thereof in all

Conditions.

Incidentally, the compounds of the formula I and also the starting materials for their preparation are prepared by methods known per se, as described in the literature (eg in the standard works such as Houben-Weyl, Methoden der organischen Chemie, Georg-Thieme-Verlag, Stuttgart), under reaction conditions which are known and suitable for the reactions mentioned. One can also make use of known per se, not mentioned here variants.

The starting compounds of the formulas II and III are generally known. If they are new, they can be produced by methods known per se. Compounds of the formula I can preferably be obtained by reacting a compound of the formula II with a compound of the formula III.

In the compounds of formula III, L preferably denotes Cl, Br, ₁ 1 or a free or reactively modified OH group such as an activated ester, an imidazolide or Alkyϊsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or aryl sulfonyloxy having 6-10 C atoms (preferably phenyl or p-Tolylsulfonyloxy).

The reaction is generally carried out in the presence of an acid-binding agent, preferably an organic base such as DIPEA, triethylamine, dimethylaniline, pyridine or quinoline. Also, the addition of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or other salt of a weak acid of the alkali or alkaline earth metals, preferably of potassium, sodium, calcium or cesium may be beneficial.

The reaction time is between a few minutes and 14 days depending on the conditions used, the reaction temperature between about

-30 ° and 140 °, normally between -10 ° and 90 °, in particular between about 0 ° and about 70 °.

Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers, such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide, 1-methyl-pyrrolidinone (NMP) or

Dimethylformamide (DMF); Nitrites such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of said solvents. Particularly preferred is acetonitrile, dichloromethane, NMP and / or DMF.

Pharmaceutical salts and other forms

The abovementioned compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases according to procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of formula I are for the most part prepared conventionally. If the compound of the formula I contains a carboxylic acid group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base addition salt. Such bases are for example

Alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and

lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and

calcium hydroxide; Alkali metal alcoholates, e.g. Potassium ethanolate and sodium propanolate; and various organic bases such as piperidine, diethanolamine and N-methylglutamine. The aluminum salts of the compounds of formula I are also included. For certain connections the

Formula I acid addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, e.g. Hydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like, and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and their corresponding salts such as acetate, trifluoroacetate, tartrate, maleate , Succinate, citrate,

Benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid addition salts include Compounds of the formula I which are: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate,

Cyclopentane propionate, digluconate, dihydrogen phosphate, dinitrobenzoate,

Dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid),

Galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate,

Metaphosphate, methanesulfonate, methyl benzoate, monohydrogen phosphate, 2-naphthalene sulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenyl acetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this is not limiting.

Furthermore, the base salts of the compounds according to the invention include aluminum, ammonium, calcium, copper, iron (III) -,

Iron (II), lithium, magnesium, manganese (III), manganese (II), potassium, sodium and zinc salts, but this is not intended to be limiting. Preferred among the above salts are ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of compounds of formula I ₁ derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, eg arginine, betaine, Caffeine, chloroprocaine, choline, N.N'-dibenzylethylenediamine (benzathine),

Dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine,

Lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine,

Piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, Triethylamine, trimethylamine, tripropylamine and tris (hydroxymethyl) - methylamine (tromethamine), but this is not intended to be limiting.

Compounds of the present invention containing basic nitrogen-containing groups can be reacted with agents such as (C ₁ -C ₄ ) alkyl halides, eg, methyl, ethyl, isopropyl, and tert-butyl chloride, bromide, and iodide; Di (Cr C ₄ ) alkyl sulfates, eg dimethyl, diethyl and diamylsulfate; (Ci ₀ - Ci ₈ ) alkyl halides, eg decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl- (C 1 -C ₄ ) alkyl halides, eg benzyl chloride and phenethyl bromide, quaternize. With such salts, both water- and oil-soluble compounds of the invention can be prepared.

Preferred pharmaceutical salts include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate,

Meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate,

Sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, which is not intended to be limiting.

Particularly preferred are hydrochloride, dihydrochloride, hydrobromide, maleate, mesylate, phosphate, sulfate and succinate.

The acid addition salts of basic compounds of formula I are prepared by contacting the free base form with a sufficient amount of the desired acid to form the salt in a conventional manner. The free base can be regenerated by contacting the salt form with a base and isolating the free base in a conventional manner. The free base forms differ, in a sense, from their corresponding salt forms with respect to certain physical ones

Properties such as solubility in polar solvents; As part of the However, the salts otherwise correspond to their respective free base forms.

As mentioned, the pharmaceutically acceptable base addition salts of the compounds of formula I are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

The base addition salts of acidic compounds of the invention are prepared by contacting the free acid form with a sufficient amount of the desired base to form the salt in a conventional manner. The free acid can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms in some sense differ from their corresponding salt forms in terms of certain physical properties such as solubility in polar

solvents; However, in the context of the invention, the salts otherwise correspond to their respective free acid forms.

If a compound according to the invention contains more than one group which can form such pharmaceutically acceptable salts, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to be limiting.

In view of the above, one sees that under the expression

"pharmaceutically acceptable salt" in the present context

An active ingredient is to be understood, which contains a compound of formula I in the form of one of its salts, especially if this salt form the Drug provides improved pharmacokinetic properties compared to the free form of the drug or any other salt form of the drug previously used. The pharmaceutically acceptable salt form of the active substance may also first impart a desired pharmacokinetic property to this active ingredient which it has not previously possessed, and may even positively influence the pharmacodynamics of this active ingredient in terms of its therapeutic activity in the body.

The invention furthermore relates to medicaments comprising at least one compound of the formula I and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants.

Pharmaceutical formulations may be presented in the form of dosage units containing a predetermined amount of active ingredient per unit dose. Such a unit may contain, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, more preferably 5 mg to 100 mg of a compound according to the invention, depending on the treatment

Disease condition, the route of administration and the age, weight and condition of the patient, or pharmaceutical formulations may be presented in the form of dosage units containing a predetermined amount of active ingredient per unit dose. Preferred unit dosage formulations are those containing a daily or partial dose as indicated above or a corresponding fraction thereof of an active ingredient. Furthermore, such pharmaceutical formulations can be prepared by any of the methods well known in the pharmaceutical art.

Pharmaceutical formulations may be administered by any suitable route, for example oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) routes. Such formulations may be prepared by any method known in the pharmaceutical art, such as by including the active ingredient with the carrier (s) or

Excipient (s) is brought together.

Pharmaceutical formulations adapted for oral administration may be administered as separate units, e.g. Capsules or tablets; Powder or granules; Solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

Thus, for example, in the oral administration in the form of a

Tablet or capsule, the active component with an oral, non-toxic and pharmaceutically acceptable inert carrier, such.

Ethanol, glycerin, water and the like. combine. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a similarly comminuted pharmaceutical excipient, e.g. an edible carbohydrate such as starch or mannitol. A flavor, preservative, dispersant and dye may also be present.

Capsules are made by preparing a powder mix as described above and filling shaped gelatin casings therewith. Lubricants and lubricants such as finely divided silica, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form can be added to the powder mixture before the filling process. A disintegrants or solubilizers such as agar-agar, calcium carbonate or sodium carbonate may also be added to improve the availability of the drug after ingestion of the capsule. In addition, if desired or necessary, suitable binding, lubricating and disintegrants as well as dyes can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, etc. Among those used in these dosage forms Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. The disintegrating agents include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry pressing , a lubricant and a disintegrant are added and the whole is compressed into tablets. A powder mixture is prepared by treating the appropriately comminuted compound with a diluent or a base as described above, and optionally with a

Binders, such as e.g. Carboxymethylcellulose, an alginate, gelatin or

Polyvinylpyrrolidone, a dissolution reducer, such as e.g. Paraffin, one

Absorption enhancer, e.g. a quaternary salt and / or an absorbent, e.g. Bentonite, kaolin or dicalcium phosphate is mixed. The powder mixture can be granulated by mixing it with a binder, e.g. Syrup, starch paste, Acadia slime or solutions of cellulose or polymer materials wetted and pressed through a sieve. As an alternative to granulation, the powder mixture can be run through a tabletting machine to produce non-uniformly shaped lumps which are broken up into granules. The granules may be greased by the addition of stearic acid, a stearate salt, talc or mineral oil to prevent sticking to the tablet molds. The greased mixture is then compressed into tablets. The compounds of the invention can also be used with a free-flowing inert

Carrier combined and then without performing the granulation or

Trockenverpressungsschritte be pressed directly into tablets. A transparent or opaque protective layer, consisting of a shellac sealant, a layer of sugar or polymeric material, and a glossy layer of wax may be present. Dyes can be added to these coatings in order to differentiate between different dosage units.

Oral fluids, e.g. Solution, syrups and elixirs may be prepared in unit dosage form such that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in an appropriate taste aqueous solution while preparing elixirs using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers, e.g. ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavoring additives such as e.g. Peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, i.a. can also be added.

The unit dosage formulations for oral administration may optionally be encapsulated in microcapsules. The formulation may also be prepared to prolong or retard release, such as by coating or embedding particulate material in polymers, wax, and the like.

The compounds of formula I as well as salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as e.g. small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.

Liposomes can be prepared from various phospholipids, such as e.g. Cholesterol,

Stearylamine or phosphatidylcholines are formed. The compounds of formula I as well as the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled with soluble polymers as targeted drug carriers. Such polymers may include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol or polyethyleneoxidepolylysine substituted with palmitoyl radicals. Further, the compounds may be coupled to a class of biodegradable polymers suitable for controlled release of a drug, eg, polylactic acid, polyepsilone-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels.

Pharmaceutical adapted to transdermal administration

Formulations can be used as separate patches for longer, narrow

Be presented with contact with the epidermis of the recipient. For example, the drug may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3 (6), 318 (1986).

Pharmaceutical compounds adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

For treatments of the eye or other external tissues, e.g. Mouth and

Skin, the formulations are preferably applied as a topical ointment or cream. When formulated into an ointment, the active ingredient may be either paraffinic or water-miscible

Cream base can be used. Alternatively, the active ingredient can become a cream be formulated with an oil-in-water cream base or a water-in-oil base.

The pharmaceutical formulations adapted for topical application to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.

To the topical application in the mouth adapted pharmaceutical

Formulations include lozenges, lozenges and mouthwashes.

Pharmaceutical formulations adapted for rectal administration may be presented in the form of suppositories or enemas.

Pharmaceutical formulations adapted for nasal administration in which the vehicle is a solid contain a coarse powder having a particle size, for example, in the range of 20-500 microns, which is administered in the manner in which snuff is received, i. by rapid inhalation via the nasal passages from a container held close to the nose with the powder. Suitable formulations for administration as a nasal spray or nasal drops with a liquid carrier include drug solutions in water or oil.

Pharmaceutical formulations adapted for administration by inhalation include fine particulate dusts or mists which may be generated by various types of pressurized dosing dispensers with aerosols, nebulizers or insufflators.

Pharmaceutical formulations adapted for vaginal administration may be used as pessaries, tampons, creams, gels, pastes, foams or

Spray formulations are presented. Pharmaceutical formulations adapted for parenteral administration include aqueous and nonaqueous sterile injection solutions containing antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient to be treated; as well as aqueous and non-aqueous sterile

Suspensions which may contain suspending agents and thickeners. The formulations may be administered in single or multiple dose containers, e.g. sealed vials and vials, and stored in the freeze-dried (lyophilized) state so that only the addition of the sterile carrier liquid, e.g. Water for injections, needed immediately before use. Injection solutions and suspensions prepared by formulation can be prepared from sterile powders, granules and tablets.

It will be understood that in addition to the above particularly mentioned ingredients, the formulations may include other means conventional in the art with respect to the particular type of formulation; for example, formulations suitable for oral administration

Flavors contain.

A therapeutically effective amount of a compound of formula I depends on a number of factors, including e.g. the age and weight of the animal, the exact condition of the disease requiring treatment, as well as its severity, the nature of the formulation and the route of administration, and is ultimately determined by the attending physician or veterinarian. However, an effective amount of a compound of the invention is useful for the treatment of neoplastic growth, e.g. Colon or breast carcinoma, generally in the range of 0.1 to 100 mg / kg body weight of the recipient (mammal) per day and more typically in the range of 1 to 10 mg / kg body weight per

Day. Thus, for a 70 kg adult mammal, the actual amount per day would usually be between 70 and 700 mg, with this amount may be given as a single dose per day or more commonly in a number of divided doses (such as two, three, four, five or six) per day so that the total daily dose is the same. An effective

Amount of a salt or solvate or a physiologically functional

Derivatives thereof can be determined as a proportion of the effective amount of the compound of the invention per se. It can be assumed that similar dosages are suitable for the treatment of the other, above-mentioned disease states.

The invention furthermore relates to medicaments comprising at least one compound of the formula I and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further active pharmaceutical ingredient.

The invention is also a set (kit), consisting of separate packages of

(A) an effective amount of a compound of formula I and / or its pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions, and

(b) an effective amount of another drug.

The kit contains suitable containers, such as boxes or boxes, individual bottles, bags or ampoules. The set may e.g. containing separate ampoules, in each of which an effective amount of a compound of formula I and / or its pharmaceutically acceptable

Salts, tautomers and stereoisomers, including mixtures thereof in all proportions, and an effective amount of another active pharmaceutical ingredient dissolved or in lyophilized form. USE

The present compounds are useful as pharmaceutical agents for mammals, particularly for humans, in the treatment of tyrosine kinase-related diseases. These diseases include proliferation of tumor cells, pathological neovascularization (or angiogenesis) that promotes solid tumor growth, neovascularization in the eye (diabetic retinopathy, age-related macular degeneration, and the like), and inflammation (psoriasis, rheumatoid arthritis, and the like ).

The present invention includes the use of the compounds of

Formula I and / or their physiologically acceptable salts and solvates

Manufacture of a medicament for the treatment or prevention of cancer.

Preferred carcinomas for the treatment are from the group of brain carcinoma, genitourinary tract carcinoma, carcinoma of the lymphatic system, gastric carcinoma, laryngeal carcinoma and lung carcinoma. Another group of preferred forms of cancer are monocytic leukemia,

Lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma and breast carcinoma. Also included is the use of the compounds of the invention according to claim 1 and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment or prevention of a disease in which angiogenesis is involved. One such disease involving angiogenesis is one

Eye disease such as retinal vascularization, diabetic retinopathy, age-related macular degeneration and the like.

The use of compounds of formula I and / or their physiologically acceptable salts and solvates for the preparation of a medicament for the treatment or prevention of inflammatory diseases is also within the scope of the present invention. To such

Inflammatory diseases include, for example, rheumatoid arthritis, Psoriasis, contact dermatitis, late-type hypersensitivity reaction, and the like.

Also included is the use of the compounds of formula I and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment or prevention of a tyrosine kinase-related disease or tyrosine kinase-related disease in a mammal, which method is given to a diseased mammal carrying such a disease Treatment requires a therapeutically effective amount of a compound of the invention administered. The therapeutic amount depends on the particular disease and can be of the

Professional without any great effort to be determined.

The present invention also encompasses the use of compounds of the formula I and / or their physiologically acceptable salts and solvates for the preparation of a medicament for the treatment or prevention of retinal vascularization. Methods for the treatment or prevention of ocular diseases such as diabetic retinopathy and age-related macular degeneration are also part of the invention. The use for treating or preventing inflammatory diseases such as rheumatoid arthritis, psoriasis, contact dermatitis and late-type hypersensitivity reactions, as well as the treatment or prevention of bone pathologies from the group of osteosarcoma, osteoarthritis and rickets, is also within the scope of the present invention. The term "tyrosine kinase-related diseases or conditions" refers to pathological conditions that are dependent on the activity of one or more tyrosine kinases.The tyrosine kinases are involved either directly or indirectly in the signal transduction pathways of various cellular activities, including proliferation, adhesion and migration as well as differentiation Diseases associated with tyrosine kinase activity include proliferation of tumor cells, pathological vascular remodeling that promotes solid tumor growth, neovascularization in the eye

(diabetic retinopathy, age-related macular degeneration and the like) as well as inflammation (psoriasis, rheumatoid arthritis and the like).

The compounds of formula I can be administered to patients for the treatment of cancer, especially fast growing tumors.

The invention thus relates to the use of compounds of the formula I ₁ and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and / or modulation of the Signal transduction of kinases plays a role.

Preference is given to the met kinase.

Preferred is the use of compounds of formula I, as well as their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions, for the manufacture of a medicament for the treatment of diseases which are affected by inhibition of the tyrosine kinases by the compounds of claim 1.

Particularly preferred is the use for the manufacture of a medicament for the treatment of diseases which are affected by inhibition of Met kinase by the compounds of claim 1. Especially preferred is the use for treating a disease wherein the disease is a solid tumor.

The solid tumor is preferably selected from the group of tumors of the lung, the squamous epithelium, the bladder, the stomach, the kidneys, the head and neck, the esophagus, the cervix, the thyroid, the intestine, liver, brain, prostate, genitourinary tract, lymphatic system, stomach and / or larynx.

The solid tumor is furthermore preferably selected from the group of lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, colon carcinoma and breast carcinoma.

Further preferred is the use for the treatment of a tumor of the blood and immune system, preferably for the treatment of a tumor selected from the group of acute myelotic leukemia, chronic myelotic leukemia, acute lymphoblastic leukemia and / or chronic lymphocytic leukemia.

The disclosed compounds of formula I may be administered in conjunction with other therapeutic agents, including anticancer agents. As used herein, the term "anticancer agent" refers to any agent that is administered to a patient with cancer for the purpose of treating the cancer.

The anticancer treatment as defined herein may be used as a sole therapy or may include conventional surgery or radiation therapy or chemotherapy in addition to the compound of the present invention. Such chemotherapy may include one or more of the following categories of antitumour agents: (i) antiproliferative / antineoplastic / DNA damaging agents and combinations thereof, as used in medical oncology, such as alkylating agents (for example, cisplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan , Chlorambucil, busulphan and nitrosoureas); Antimetabolites (e.g., antifolates, such as fluoropyrimidines, such as

Fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside,

Hydroxyurea and gemcitabine); Anti-tumor antibiotics (eg anthracyclines such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, Mitomycin C, dactinomycin and mithramycin); antimitotic agents (for example, vinca alkaloids such as vincristine, vinblastine, vindesine and vinorelbine, and taxoids such as taxol and taxotere); Topoisomerase inhibitors (for example, epipodophyllotoxins, such as etoposide and teniposide, amsacrine, topotecan, irinotecan, and camptothecin) and cell-differentiating agents (for example, all-trans-retinoic acid, 13-cis-retinoic acid, and fenretinide); (ii) cytostatic agents such as anti-estrogens (eg tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfen), estrogen receptor downregulating agents (eg fulvestrant), anti-androgens (eg

Bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progesterone (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5α-reductase, such as finasteride;

(iii) agents that inhibit the invasion of cancer cells (for example metalloproteinase inhibitors, such as marimastat and inhibitors of urokinase).

Plasminogen activator receptor function);

(iv) inhibitors of growth factor function, for example, such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example, the anti-erbb2 antibody trastuzumab [Herceptin ™] and the anti-erbb1 antibody cetuximab [C225]), Famesyltransferase inhibitors, tyrosine kinase inhibitors and serine / threonine

Kinase inhibitors, for example, epidermal growth factor family inhibitors (for example, EGFR family tyrosine kinase inhibitors, such as N- (3-chloro-4-fluorophenyl) -7-methoxy-6- (3-morpholinopropoxy) quinazoline). 4-amine (gefitinib, AZD1839), N- (3-ethynylphenyl) -6,7-bis (2-methoxyethoxy) quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-fvJ- (3-chloro 4-fluorophenyl) -7- (3-morpholinopropoxy) quinazolin-4-amine (Cl 1033)), for example platelet-derived growth factor family inhibitors and, for example, inhibitors of the hepatocyte growth factor family; (v) antiangiogenic agents, such as those which inhibit the effects of vascular endothelial growth factor (for example, the vascular endothelial cell growth factor bevacizumab antibody [Avastin ™], compounds such as those disclosed in published international patent applications WO 97/22596, WO 97 / 30035, WO 97/32856 and WO

98/13354) and compounds that act by other mechanisms (for example, linomide, integrin αvβ3 inhibitors, and angiostatin); (vi) vascular damaging agents such as combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; (vii) antisense therapies, for example, those directed against the targets listed above, such as ISIS 2503, an anti-Ras

Antisense;

(viii) gene therapy approaches, including, for example, approaches to

Replacement of altered genes, such as altered p53 or altered

BRCA1 or BRCA2, GDEPT- (gene-directed enzyme pro-drug therapy)

Approaches using those that include cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme, as well as approaches to increasing patient tolerance to chemotherapy or radiation therapy, such as multi-drug resistance gene therapy; and

(ix) immunotherapy approaches, including, for example, ex vivo and in vivo approaches to increase the immunogenicity of patient tumor cells such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to reduction T cell anergy, batches using transfected immune cells such as cytokine-transfected dendritic cells, batches using cytokine-transfected tumor cell lines, and anti-idiotypic antibody approaches. Preferably, but not exclusively, the medicaments of Table 1 below are combined with the compounds of the formula I.

Table 1.

Alkylating agent Cyclophosphamide Lomustine

Busulfan procarbazine

Ifosfamide altretamine

Melphalan estramustin phosphate

Hexamethylmelamine mechlorethamine

Thiotepa streptozocin

Chlorambucil Temozolomide

Dacarbazine Semustin

carmustine

Platinum agent cisplatin carboplatin

Oxaliplatin ZD-0473 (AnorMED)

Spiroplatin Lobaplatin (Aetema)

Carboxyphthalatoplatinum Satraplatin (Johnson

Tetraplatinum Matthey)

Ormiplatin BBR-3464 (Hoffrnann-La

Iproplatin Roche)

SM-11355 (Sumitomo)

AP-5280 (Access)

Antimetabolite azacytidine Tomudex

Gemcitabine trimetrexate

Capecitabine deoxycoformycin

5-fluorouracil fludarabine

Floxuridine pentostatin

2-chlorodeoxyadenosine Raltitrexed

6-mercaptopurine hydroxyurea

6-thioguanine decitabine (SuperGen)

Cytarabine Clofarabine (Bioenvision)

2-Fluorodeoxycytidine Irofulvene (MGI Pharma)

Methotrexate DMDC (Hoffmann-La Roche

Idatrexate Ethinylcytidine (Taiho)

Topoisomerase Amsacrine Rubitecane (SuperGen)

Inhibitors Epirubicin Exatecan Mesylate (Daiichi)

Etoposide Quinamed (ChemGenex)

Teniposide or mitoxantrone gimatecan (Sigma-Tau) lrinotecan (CPT-11) diflomotecan (Beaufour

7-ethyl-10-Ipsen) hydroxycamptothecin TAS-103 (Taiho)

Topotecan Elsamitrucin (Spectrum) Dexrazoxanet (TopoTarget) J-107088 (Merck & Co)

Pixantrone (Novuspharma) BNP-1350 (BioNumerik)

Rebeccamycin analog CKD-602 (Chong Kun Dang

(Exelixis) KW-2170 (Kyowa Hakko)

BBR-3576 (Novuspharma)

Antitumor Dactinomycin (Actinomycin Amonafide

Antibiotics D) Azonafide

Doxorubicin (adriamycin) anthrapyrazole

Deoxyrubicin Oxantrazole

Valrubicin losoxantrone

Daunorubicin (Daunomycin) Bleomycin Sulfate (Blenoxan)

Epirubicin bleomycinic acid

Therarubicin Bleomycin A

Idarubicin bleomycin B

Rubidazone mitomycin C

Plicamycin p MEN-10755 (Menarini)

Porfiromycin GPX-100 (gem

Cyanomorpholinodoxorubici Pharmaceuticals)

Mitoxantrone (Novantrone)

Antimitotic Center Paclitaxel SB 408075

Docetaxel (GlaxoSmithKline)

Colchicine E7010 (Abbott)

Vinblastine PG-TXL (Cell Therapeutics)

Vincristine IDN 5109 (Bayer)

Vinorelbine A 105972 (Abbott)

Vindesin A 204197 (Abbott)

Dolastatin 10 (NCI) LU 223651 (BASF)

Rhizoxin (Fujisawa) D 24851 (ASTA Medica)

Mivobulin (Warner-Lambert) ER-86526 (Eisai)

Cemadotin (BASF) Combretastatin A4 (BMS)

RPR 109881A (Aventis) isohomohalichondrin-B

TXD 258 (Aventis) (PharmaMar)

Epothilone B (Novartis) ZD 6126 (AstraZeneca)

T 900607 (Tularik) PEG paclitaxel (Enzon)

T 138067 (Tularik) AZ10992 (Asahi)

Cryptophycin 52 (Eli Lilly)! DN-5109 (lndena)

Vinflunin (Fabre) AVLB (Prescient

Auristatin PE (Teikoku NeuroPharma)

Hormones) azaepothilone B (BMS)

BMS 247550 (BMS) BNP-7787 (BioNumerik)

BMS 184476 (BMS) CA-4 prodrug (OXiGENE)

BMS 188797 (BMS) Dolastatin-10 (NrH)

Taxoprexin (Protarga) CA-4 (OXiGENE)

Aromatase I aminoglutethimide exemestane Immunomodulator Interferon Dexosome Therapy (Anosys

Oncophage (Antigenics) Pentrix (Australian Cancer

GMK (Progenics) Technology)

Adenocarcinoma vaccine JSF-154 (Carrying)

(Biomira) cancer vaccine (Intercell)

CTP-37 (AVI BioPharma) Norelin (Biostar)

JRX-2 (Immuno-Rx) BLP-25 (Biomira)

PEP-005 (Peplin Biotech) MGV (Progenics)

Synchrovax vaccines (CTL! 3-alethine (Dovetail)

Immuno) CLL-Thera (Vasogen)

Melanoma vaccine (CTL

Immuno) p21 RAS vaccine

(GemVax)

Hormonal and estrogenic prednisone antihormonal conjugated estrogens methylprednisolone

Agent ethinyl estradiol prednisolone

Chlorotrienes Aminoglutethimide

Idenestrol Leuprolide

Hydroxyprogesterone caproate goserelin

Medroxyprogesterone Leuporelin

Testosterone Bicalutamide

Testosterate Propylate Flutamide

Fluoxymesterone octreotide

Methyltestosterone Nilutamide

Diethylstilbestrol Mitotane

Megestrol P-04 (Novogen)

Tamoxifen 2-methoxyestradiol

Toremofin (EntreMed)

Dexamethasone Arzoxifen (EIi Lilly)

Photodynamic Talaporfin (Light Sciences) Pd-Bacteriopheophorbide

Central Theralux (Yeda)

(Theratechnologies) Lutetium Texaphyrin

Motexafin Gadolinium (Pharmacyclics)

(Pharmacyclics) Hypericin

Tyrosine kinase imatinib (Novartis) Kahalid F (PharmaMar)

Inhibitors Leflunomide CEP-701 (Cephalon)

(Sugen / Pharmacia) CEP-751 (Cephalon)

ZDI839 (AstraZeneca) MLN518 (Millenium)

Erlotinib (Oncogene Science PKC412 (Novartis)

Canertjnib (Pfizer) phenoxodiol O

Squalamine (Genaera) trastuzumab (Genentech)

SU5416 (Pharmacia) C225 (ImCIone)

SU6668 (Pharmacia) rhu-Mab (Genentech) ZD4190 (AstraZeneca) MDX-H210 (Medarex)

ZD6474 (AstraZeneca) 2C4 (Genentech)

Vatalanib (Novartis) MDX-447 (Medarex)

PKI166 (Novartis) ABX-EGF (Abgenix)

GW2016 (GlaxoSmithKline) IMC-1C11 (ImCIone)

EKB-509 (Wyeth)

EKB-569 (Wyeth)

Various center SR-27897 (CCK-A inhibitor, BCX-1777 (PNP inhibitor,

Sanofi-Synthelabo) BioCryst)

Tocladesin (Cyclic AMP Ranpimase (Ribonuclease

Agonist, ribapharm) stimulant, Alfacell)

Alvocidib (CDK inhibitor, galarubicin (RNA synthesis

Aventis) inhibitor, Dong-A)

CV-247 (COX-2 inhibitor, Iv, tirapazamine

Medical) (reducing agent, SRI

P54 (COX-2 inhibitor, International)

Phytopharm) N-acetylcysteine

CapCell ™ (CYP450- (Reducing Agent, Zambon)

Stimulans, Bavarian Nordic) R-Flurbiprofen (NF-kappaB-

GCS-IOO (gal3 antagonist, inhibitor, Encore)

GlycoGenesys) 3CPA (NF-kappaB inhibitor

G17DT immunogen (Gastrir Active Biotech)

Inhibitor, Aphton) seocalcitol (vitamin D

Efaproxiral (oxygenator, receptor agonist, Leo)

Allos Therapeutics) 131-I-TM-601 (DNA

PI-88 (heparanase inhibitor antagonist, TransMolecular

Progene) Eflomithine (ODC inhibitor,

Tesmilifen (histamine ILEX oncology)

Antagonist, YM BioSciences Minodronic Acid

Histamine (histamine H2 (osteoclast inhibitor,

Receptor agonist, Maxim) Yamanouchi)

Tiazofurin (IMPDH inhibitor, indisulam (p53 stimulant,

Ribapharm) Eisai)

Cilengitide (Integrin Aplidine (PPT inhibitor,

Antagonist, Merck KGaA) PharmaMar)

SR-31747 (IL-1 antagonist, rituximab (CD20 Antikörpeι

Sanofi-Synthelabo) Genentech)

CCI-779 (mTOR kinase gemtuzumab (CD33-

Inhibitor, Wyeth) antibodies, Wyeth Ayerst)

Exisulind (PDE-V inhibitor, PG2 (hematopoietic

Cell Pathways) Amplifier 'Pharmagenesis ^'

CP-461 (PDE-V inhibitor, Immunol ™ (triclosan)

Cell Pathways) Oral Irrigation, Endo)

AG-2037 (GART inhibitor, triacetyluridine (uridine)

Pfizer) prodrug, Wellstat)

WX-UK1 SN-4071 (sarcoma agent,

(Plasminogen activator Signature BioScience) Inhibitor, Wilex) TransMID-107 ™

PBI-1402 (PMN stimulant, (immunotoxin, KS Biomedix

ProMetic LifeSciences) PCK-3145 (apoptosis

Bortezomib (proteasome promoter, Procyon)

Inhibitor, millennium) doranidazole (apoptosis

SRL-172 (T-cell stimulant, promoter, PoIa)

SR Pharma) CHS-828 (cytotoxic

TLK-286 (glutathione-S agent, Leo)

Transferase inhibitor, Telik) trans -retinoic acid

PT-100 (growth factor (differentiator, NIH)

Agonist, Point Therapeutics ^ MX6 (apoptosis promoter,

Midostaurin (PKC inhibitor, MAXIA)

Novartis) apomin (apoptosis promotion

Bryostatin-1 (PKC stimulant; ILEX Oncology)

GPC Biotech) Urocidin (Apoptosis-Fördere

CDA-II (Apoptosis promoter, Bioniche)

Everiife) Ro-31-7453 (apoptosis

SDX-101 (Apoptosis promoter, La Roche)

Promoter, salmedix) brostallicin (apoptosis

Ceflatonin (Apoptosis promoter, Pharmacia)

Conveyor, ChemGenex)

Alkylating agent Cyclophosphamide Lomustine

Busulfan procarbazine

Ifosfamide altretamine

Melphalan estramustin phosphate

Hexamethylmelamine mechlorethamine

Thiotepa streptozocin

Chlorambucil Temozolomide

Dacarbazine Semustin

carmustine

Platinum agent cisplatin carboplatin

Oxaliplatin ZD-0473 (AnorMED)

Spiroplatin Lobaplatin (Aetema)

Carboxyphthalatoplatinum Satraplatin (Johnson

Tetraplatinum Matthey)

Ormiplatin BBR-3464 (Hoffrnann-La

Iproplatin Roche)

SM-11355 (Sumitomo)

AP-5280 (Access) Antimetabolite azacytidine Tomudex

Gemcitabine trimetrexate

Capecitabine deoxycoformycin

5-fluorouracil fludarabine

Floxuridine pentostatin

2-chlorodeoxyadenosine Raltitrexed

6-mercaptopurine hydroxyurea

6-thioguanine decitabine (SuperGen)

Cytarabine Clofarabine (Bioenvision)

2-Fluorodeoxycytidine Irofulvene (MGI Pharma)

Methotrexate DMDC (Hoffmann-La Roch)

Idatrexate Ethinylcytidine (Taiho)

Topoisomerase Amsacrine Rubitecane (SuperGen)

Inhibitors Epirubicin Exatecan Mesylate (Daiichi)

Etoposide Quinamed (ChemGenex)

Teniposide or Mitoxantrone Gimatecan (Sigma-Tau)

Irinotecan (CPT-11) diflomotecan (Beaufour

7-ethyl-10-Ipsen) hydroxycamptothecin TAS-103 (Taiho)

Topotecan Elsamitrucin (Spectrum)

Dexrazoxanet (TopoTarget) J-107088 (Merck & Co)

Pixantrone (Novuspharma) BNP-1350 (BioNumerik)

Rebeccamycin analog CKD-602 (Chong Kun Dans

(Exelixis) KW-2170 (Kyowa Hakko)

BBR-3576 (Novuspharrna)

Antitumor Dactinomycin (Actinomycin Amonafide

Antibiotics D) Azonafide

Doxorubicin (adriamycin) anthrapyrazole

Deoxyrubicin Oxantrazole

Valrubicin losoxantrone

Daunorubicin (Daunomycin) Bleomycin Sulfate (Blenoxan)

Epirubicin bleomycinic acid

Therarubicin Bleomycin A

Idarubicin bleomycin B

Rubidazone mitomycin C

Plicamycin p MEN-10755 (Menarini)

Porfiromycin GPX-100 (gem

Cyanomorpholinodoxorubici Pharmaceuticals)

Mitoxantrone (Novantrone) Anti-mitotic center Paclitaxel SB 408075

Docetaxel (GlaxoSmithKline)

Colchicine E7010 (Abbott)

Vinblastine PG-TXL (Cell Therapeutics)

Vincristine IDN 5109 (Bayer)

Vinorelbine A 105972 (Abbott)

Vindesin A 204197 (Abbott)

Dolastatin 10 (NCI) LU 223651 (BASF)

Rhizoxin (Fujisawa) D 24851 (ASTA Medica)

Mivobulin (Warner-Lambert ER-86526 (Eisai)

Cemadotin (BASF) Combretastatin A4 (BMS)

RPR 109881A (Aventis) isohomohalichondrin-B

TXD 258 (Aventis) (PharmaMar)

Epothilone B (Novartis) ZD 6126 (AstraZeneca)

T 900607 (Tularik) PEG paclitaxel (Enzon)

T 138067 (Tularik) AZ10992 (Asahi)

Cryptophycin 52 (Eli Lilly)! DN-5109 (lndena)

Vinflunin (Fabre) AVLB (Prescient

Auristatin PE (Teikoku NeuroPharma)

Hormones) azaepothilone B (BMS)

BMS 247550 (BMS) BNP-7787 (BioNumerik)

BMS 184476 (BMS) CA-4 prodrug (OXiGENE)

BMS 188797 (BMS) Dolastatin-10 (NrH)

Taxoprexin (Protarga) CA-4 (OXiGENE)

Aromatase-aminoglutethimide exemestane

Inhibitors Letrozole Atamestane (BioMedicines)

Anastrazole YM-511 (Yamanouchi)

formestane

Thymidylate synthas «Pemetrexed (EIi Lilly) Nolatrexed (Eximias)

Inhibitors ZD-9331 (BTG) CoFactor ™ (BioKeys)

DNA antagonists Trabectedin (PharmaMar) Mafosfamide (Baxter

Glufosfamide (Baxter International)

International) Apaziquon (Spectrum

Albumin + 32P (Isotope Pharmaceuticals)

Solutions) O6 Benzylguanine (Paligent)

Thymectacin (NewBiotics)

Edotreotide (Novartis)

Farnesyltransferas «Arglabin (NuOncology Labs) Tipifarnib (Johnson & Johnson)

Inhibitors lonafarnib (Schering-Plow Johnson)

BAY-43-9006 (Bayer) Perillyl Alcohol (DOR

BioPharma) Pump inhibitor CBT-1 (CBA Pharma) Zosuquidar trihydrochloride

Tariquidar (Xenova) (Eli Lilly)

MS-209 (Schering AG) Biricodar dicitrate (vertex)

Histone acetyltransfer tacedinalin (Pfizer) pivaloyloxymethyl butyrate ase- SAHA (Aton Pharma) (titanium)

Inhibitors MS-275 (Schering AG) Depsipeptide (Fujisawa)

Metalloproteinase neovastate (Aeterna CMT -3 (CollaGenex)

Inhibitors Laboratories) BMS-275291 (Celltech)

Ribonucleosidredul Marimastat (British Biotech) Tezacitabine (Aventis) ase Gallium Maltolate (Titanium) Didox (Molecules for Health

Inhibitors Triapine (Vion)

TNF-alpha-virulizine (Lorus Therapeutics Revimid (Celgene)

Agonists / antagon CDC-394 (Celgene) th

Endothelin A Atrasentan (Abbot) YM-598 (Yamanouchi)

Receptor ZD-4054 (AstraZeneca)

antagonists

Retinoic Acid Fenretinide (Johnson & Alitretinoin (Ligand)

Agonist Johnson)

LGD-1550 (ügand)

Immunomodulator Interferon Dexosome Therapy (Anosys

Oncophage (Antigenics) Pentrix (Australian Cancer

GMK (Progenics) Technology)

Adenocarcinoma vaccine JSF-154 (Carrying)

(Biomira) cancer vaccine (Intercell)

CTP-37 (AVI BioPharma) Norelin (Biostar)

JRX-2 (Immuno-Rx) BLP-25 (Biomira)

PEP-005 (Peplin Biotech) MGV (Progenics)

Synchrovax vaccines (CTL! 3-alethine (Dovetail)

Immuno) CLL-Thera (Vasogen)

Melanoma vaccine (CTL

Immuno) p21 RAS vaccine

(GemVax) Hormonal and estrogenic prednisone antihormonal conjugated estrogens methylprednisolone

Agent ethinyl estradiol prednisolone

Chlorotrienes Aminoglutethimide

Idenestrol Leuprolide

Hydroxyprogesterone caproal goserelin

Medroxyprogesterone Leuporelin

Testosterone Bicalutamide

Testosterone Propionate Flutamide

Fluoxymesterone octreotide

Methyltestosterone Nilutamide

Diethylstilbestrol Mitotane

Megestrol P-04 (Novogen)

Tamoxifen 2-methoxyestradiol

Toremofin (EntreMed)

Dexamethasone Arzoxifen (EIi Lilly)

Photodynamic Talaporfin (Light Sciences) Pd-Bacteriopheophorbide

Central Theralux (Yeda)

(Theratechnologies) Lutetium Texaphyrin

Motexafin Gadolinium (Pharmacyclics)

(Pharmacyclics) Hypericin

Tyrosine kinase imatinib (Novartis) Kahalid F (PharmaMar)

Inhibitors Leflunomide CEP-701 (Cephalon)

(Sugen / Pharmacia) CEP-751 (Cephalon)

ZDI839 (AstraZeneca) MLN518 (Millenium)

Erlotinib (Oncogene Scienc E PKC412 (Novartis)

Canertjnib (Pfizer) phenoxodiol O

Squalamine (Genaera) trastuzumab (Genentech)

SU5416 (Pharmacia) C225 (ImCIone)

SU6668 (Pharmacia) rhu-Mab (Genentech)

ZD4190 (AstraZeneca) MDX-H210 (Medarex)

ZD6474 (AstraZeneca) 2C4 (Genentech)

Vatalanib (Novartis) MDX-447 (Medarex)

PK1166 (Novartis) ABX-EGF (Abgenix)

GW2016 (GlaxoSmithKlinej IMC-1C11 (ImCIone)

EKB-509 (Wyeth)

EKB-569 (Wyeth)

Various center SR-27897 (CCK-A inhibitor BCX-1777 (PNP inhibitor,

Sanofi-Synthelabo) BioCryst)

Tocladesin (cyclic ranitimase (ribonuclease)

AMP agonist, ribapharm) stimulant, Alfacell)

Alvocidib (CDK inhibitor, galarubicin (RNA synthesis

Aventis) inhibitor, Dong-A)

CV-247 (COX-2 inhibitor, tirapazamine Ivy Medical) (reducing agent, SRI

P54 (COX-2 inhibitor, International)

Phytopharm) N-acetylcysteine

CapCell ™ (CYP450- (Reducing Agent, Zambon)

Stimulant, Bavarian Nordic R-Flurbiprofen (NF-kappaB-

GCS-IOO (gal3 antagonist, inhibitor, Encore)

GlycoGenesys) 3CPA (NF-kappaB inhibitor,

G17DT Immunogen Active Biotech)

(Gastrin inhibitor, Aphton) seocalcitol (vitamin D

Efaproxiral (oxygenator, receptor agonist, Leo)

Allos Therapeutics) 131-I-TM-601 (DNA

PI-88 (Heparanase Inhibitor Antagonist, TransMolecular)

10 progens) eflornithine (ODC inhibitor,

Tesmilifen (histamine ILEX oncology)

Antagonist, YM Minodronic Acid

BioSciences) (osteoclast inhibitor,

Histamine (histamine H2-yamanouchi)

Receptor agonist, Maxim) Indisulam (p53 stimulant,

15 tiazofurin (IMPDH inhibitor Eisai)

Ribapharm) aplidine (PPT inhibitor,

Cilengitide (Integrin PharmaMar)

Antagonist, Merck KGaA) Rituximab (CD20 antibody

SR-31747 (IL-1 antagonist, Genentech)

Sanofi-Synthelabo) gemtuzumab (CD33-

CCI-779 (mTOR kinase antibody, Wyeth Ayerst)

20 inhibitor, Wyeth) PG2 (hematopoietic

Exisulind (PDE-V inhibitor, enhancer, pharmacogenesis)

Cell Pathways) Immunol ™ (Triclosan

CP-461 (PDE-V inhibitor, oral rinse, endo)

Cell Pathways) triacetyluridine (uridine

AG-2037 (GART inhibitor, prodrug, Wellstat)

Pfizer) SN-4071 (sarcoma agent,

25

WX-UK1 Signature BioScience)

(Plasminogen Activator TransMID-107 ™

Inhibitor, Wilex) (immunotoxin, KS Biomedix)

PBI-1402 (PMN stimulant, PCK-3145 (apoptosis

ProMetic LifeSciences) conveyor, Procyon)

Bortezomib (proteasome doranidazole (apoptosis)

30 inhibitor, Millennium) promoter, PoIa)

SRL-172 (T cell stimulant, CHS-828 (cytotoxic

SR Pharma) agent, Leo)

TLK-286 (glutathione-S-trans-retinoic acid

Transferase inhibitor, TeNk; (Differentiator, NIH)

PT-100 (growth factor MX6 (apoptosis promoter,

Agonist, Point Therapeutics MAXIA)

35 Midostaurin (PKC inhibitor, apomin (apoptosis promoter,

Novartis) ILEX Oncology) Bryostatin-1 (PKC-uridine (apoptosis promoter

Stimulant, GPC Biotech) Bioniche)

CDA-II (apoptosis promoter Ro-31-7453 (apoptosis

Everlife) promoter, La Roche)

SDX-101 (apoptosis-brostallicin (apoptosis)

Promoter, Salmedix) promoter, Pharmacia)

Ceflatonin (apoptosis

Conveyor, ChemGenex)

Such joint treatment can be achieved by simultaneously, sequentially or separately dosing the individual components of the treatment. Such combination products employ the compounds of the invention.

ASSAYS

The compounds of formula I described in the Examples were tested in the assays described below and found to have kinase inhibitory activity. Other assays are known in the literature and could be readily performed by those skilled in the art (see, eg, Dhanabal et al., Cancer Res. 59: 189-197; Xin et al., J. Biol. Chem. 274: 9116-9121; Sheu et Biol. 38: 237-248; Gimbrone et al., J. Natl. Cancer Inst. 52: 413-427; Nicosia et al., Anticancer Res. 18: 4435-4441; Ausprunk et al., Dev. In Vitro 18: 538-549).

Measurement of Met kinase activity

According to the manufacturer (Met, active, upstate, catalog No. 14-526), the Met kinase is recombinantly human as "N-terminally 6His tagged" for the purpose of protein production in insect cells (Sf21, S. frugiperda) and subsequent affinity chromatographic purification Protein expressed in a baculovirus expression vector. To measure the kinase activity can be made of various available measuring systems. In scintillation proximity (Sorg et al., J. of Biomolecular Screening, 2002, 7, 11-19), the FlashPlate method or the filter binding assay, the radioactive phosphorylation of a protein or peptide as a substrate with radioactively labeled ATP ( ³² P-ATP, ³³ P-ATP). In the presence of an inhibitory compound, no or a reduced radioactive signal is detectable. Further, Homogeneous Time-resolved Fluorescence Resonance Energy Transfer (HTR-FRET) and Fluorescence Polarization (FP) technologies are useful as assay methods (SiIIs et al., J. of Biomolecular Screening, 2002, 191-214).

Other non-radioactive ELISA assay methods use specific phospho-antibodies (Phospho-AK). The phospho-antibody binds only the phosphorylated substrate. This binding is detectable by chemiluminescence with a second peroxidase-conjugated antibody (Ross et al., 2002, Biochem. J.).

Flashplate method (Met kinase):

The test plates are 96-well Flashplate ^R microtiter plates from Perkin Elmer (Cat. No. SMP200). The components of the kinase reaction described below are pipetted into the assay plate.

The Met kinase and the substrate poly Ala-Glu-Lys-Tyr, (pAGLT, 6: 2: 5: 1). ^ be radiolabeled P-ATP in the presence and absence of

Test substances in a total volume of 100 .mu.l incubated at room temperature for 3 hrs. The reaction is stopped with 150 μl of a 6OmM EDTA solution. After incubation for a further 30 min at room temperature, the supernatants are filtered off with suction and the wells are washed three times with 200 μl each of 0.9% NaCl solution. The measurement of the bound radioactivity is carried out by means of a scintillation meter (Topcount NXT, Perkin-Elmer). As a whole, the inhibitor-free kinase reaction is used. This should be approximately in the range of 6000-9000 cpm. The pharmacological zero value used is staurosporine at a final concentration of 0.1 mM. A Determination of the inhibition values (IC50) is carried out using the program RS1_MTS ().

Kinase reaction conditions per well: 30 μl assay buffer

10 μl substance to be tested in assay buffer with 10% DMSO 10 μl ATP (final concentration 1 μM cold, 0.35 μCi ³³ P-ATP) 50 μl mixture Met kinase / substrate in assay buffer; (10 ng enzyme / well, 50 ng pAGLT / well)

Used solutions:

Assay buffer: 50 mM HEPES

3 mM magnesium chloride 3 μM sodium orthovanadate 3 mM manganese (II) chloride 1 mM dithiothreitol (DTT) pH = 7.5 (adjust with sodium hydroxide)

- Stop solution:

60mM Titriplex III (EDTA)

- ³³ P-ATP: Perkin-Elmer;

- Met Kinase: Upstate, cat.-no. 14-526, stock 1 μg / 10 μl; spec.

Activity 954 U / mg;

Poly-Ala-Glu-Lys-Tyr, 6: 2: 5: 1: Sigma Cat. P1152

Above and below all temperatures are given in ⁰ C. In the following examples, "usual workup" means adding water if necessary, adjusting to pH values between 2 and 10, if necessary, depending on the constitution of the final product, extracting with ethyl acetate or dichloromethane, separating, drying organic phase over sodium sulfate, evaporated and purified by chromatography on silica gel and / or by crystallization. Rf values on silica gel; Eluent: ethyl acetate / methanol

9: 1st

Melting point F. in ⁰ C;

Mass spectrometry (MS): El (Electron Impact Ionization) M ⁺ FAB (Fast Atom Bombardment) (M + H) ⁺

ESI (electrospray ionization) (M + H) ⁺

APCI-MS (atmospheric pressure chemical ionization - mass spectrometry)

(M + H) ⁺ .

HPLC method:

Flow rate: 2 ml / min

99:01 - 0: 100 water + 0.1% (vol.) TFA: acetonitrile + 0.1% (vol.) TFA 0.0 to 0.2 min: 99:01

0.2 to 3.8 min: 99: 01-> 0: 100

3.8 to 4.2 min: 0: 100

Column: Chromolith Performance RP18e; 100 mm long, inner diameter 3 mm, wavelength: 220 nm

example 1

The preparation of 3- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl} -5-trifluoromethyl-3H-benzothiazol-2-one ("Al") occurs analogously to the following scheme

Step 1 :

Preparation of 3- (N-hydroxycarbamimidoyl) benzoic acid:

1382 g (10.0 mol) of potassium carbonate are added in portions to a suspension of 500 g (3.40 mol) of 3-cyanobenzoic acid in 8 l of methanol at 30 ° C., with stirring. Subsequently, at an internal temperature of 40-45 ° C 695 g (10.0 mol) of hydroxylammonium chloride added in small portions. Then the reaction mixture is heated to boiling for 15 hours. The reaction mixture is concentrated in vacuo, the residue dissolved in water and acidified with 37% aqueous hydrochloric acid. The resulting precipitate is filtered off with suction, washed with water and dried in vacuo: 3- (N-hydroxycarbamimidoyl) benzoic acid as colorless crystals; F. 208 °; ESI 181 (M + H).

Level 2:

Preparation of 3- (5-methyl- [1,2,4] oxadiazol-3-yl) benzoic acid:

A mixture of 614 g (3.41 mol) of 3- (N-hydroxycarbamimidoyl) benzoic acid, 756 ml (8.0 mol) acetic anhydride and 2 l acetic acid is heated to a temperature of 118 ° C for 14 hours. The reaction mixture is cooled to 6 ° C and filtered with suction. The residue is taken up in 2 l of water, filtered off with suction and washed well with water. The residue is recrystallised from ethanol / water: 3- (5-methyl- [1,2,4] oxadiazol-3-yl) benzoic acid as colorless crystals; Mp 225 °; ESl 205 (M + H).

Level 3:

Preparation of 3- (5-methyl- [1,2,4] oxadiazol-3-yl) -benzoic acid methyl ester:

A suspension of 30.0 g (147 mmol) of 3- (5-methyl- [1,2,4] oxadiazol-3-yl) benzoic acid in 150 ml of methanol is treated with 7.83 ml (147 mmol) of concentrated sulfuric acid and 18 hours for Boil boiling. The reaction mixture is cooled in an ice bath, combined with water, filtered off with suction and washed well with water: methyl 3- (5-methyl-1,2,4-oxadiazol-3-yl) benzoate as colorless crystals; F. 81 ⁰ C, ESI 219 (M + H), HPLC: Rt. = 2.65 min (Method A).

Level 4:

Preparation of methyl 3-carbamimidoyl-benzoate acetate: A solution of 327 g (1.47 mol) of methyl 3- (5-methyl- [1,2,4] oxadiazol-3-yl) benzoate in 3 l of methanol is washed with 150 ml of acetic acid, 150 ml of water and 50 g of water-moist Raney nickel added and 18 hours at

Room temperature and normal pressure hydrogenated. The catalyst is filtered off and the filtrate is evaporated. The residue is taken up in te / t-butyl methyl ether, heated to boiling and filtered off with suction. The residue is dried in vacuo: 3-methoxycarbonylbenzamidinium acetate as colorless crystals; F. 222 °; ESI 179 (M + H); HPLC: Rt. = 1.40 min (Method A). 0

Level 5:

Preparation of methyl 3- [5- (dimethylamino-methyleneamino) -pyrimidin-2-yl] benzoate: To a suspension of 259 g (1.09 mol) of 3-methoxycarbonylbenzamidinium acetate and 528 g (1.08 mol) ({2 -Dimethylamino-1- [dimethyl-immoniomethyl] -vinylamino} -methylene) -dimethylammonium-di-hexafluorophosphate ("aminoreductone precursor", prepared according to CB 0 Dousson et al., Synthesis 2005, 1817) in 1 l of methanol 2.2 l of a freshly prepared 1.5 M sodium methoxide solution are added dropwise with stirring, then the reaction mixture is heated to 60 ° C. in the course of 40 minutes and kept at this temperature for 30 minutes

Reaction mixture cooled to room temperature, diluted with 10 l of dichloromethane5 and washed three times with 5 l of water. The organic phase is dried over sodium sulfate and evaporated. The residue is recrystallised from ethyl acetate: methyl 3- [5- (dimethylamino-methyleneamino) -pyrimidin-2-yl] -benzoate as beige crystals; Mp 146 ° C, ESI 285 (M + H), ⁰ HPLC: Rt = 2.03 min (Method A).

Level 6:

Preparation of 3- (5-hydroxy-pyrimidin-2-yl) benzoic acid: 5 A suspension of 103.5 g (364 mmol) of ethyl 3- [5- (dimethylamino-methylene-amino) -pyrimidin-2-yl] benzoate 1.3 I water gets 160 ml (2.88 mol) of concentrated sulfuric acid and heated to boiling for 4 hours. The reaction mixture is cooled to room temperature, diluted with water and filtered with suction. The residue is washed with water and dried in vacuo: 3- (5-hydroxypyrimidin-2-yl) benzoic acid as brownish crystals; F. 293-295 °; ESI 217 (M + H); HPLC: Rt.

= 2.19 min (method A).

Level 7:

Preparation of 3- (5-hydroxy-pyrimidin-2-yl) -benzoic acid methyl ester:

A suspension of 88.0 g (366 mmol) of 3- (5-hydroxypyrimidin-2-yl) -benzoic acid in 1.4 l of methanol is treated with 32.7 ml (445 mmol) of thionyl chloride and heated to 80 ° C. for 2 hours. Then 20 ml (276 mmol) of thionyl chloride and after 2 hours another 10 ml (138 mmol) of thionyl chloride are added. After each addition, the reaction mixture is stirred for 2 hours at 80 ° C. The reaction mixture is concentrated in vacuo to a volume of about 300 ml. The resulting precipitate is filtered off and dried in vacuo: methyl 3- (5-hydroxypyrimidin-2-yl) benzoate as brownish crystals; F. 219-223 °; ESI 231 (M + H); HPLC: Rt. = 2.58 min (Method A).

Stage 8:

Preparation of 3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzoic acid methyl ester:

A solution, kept under nitrogen, of 10.1 g (44 mmol) of ethyl 3- (5-hydroxy-pyrimidin-2-yl) benzoate, 17.3 g (66 mmol) of triphenylphosphine and 5.9 ml (48.4 mmol) of 2-morpholin-4-yl ethanol in 100 ml of THF is cooled in an ice bath and 12.95 ml (66 mmol) of diisopropyl azodicarboxylate are slowly added dropwise with stirring. After stirring for 2 hours at room temperature, the reaction mixture is evaporated in vacuo. The residue is taken up in 100 ml of dichloromethane and 100 ml of water. The organic phase is dried over sodium sulfate and evaporated. The residue is recrystallized from isopropanol: methyl 3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzoate as beige-colored crystals; F. 89-91 °; ESI 344 (M + H); HPLC: 2.06 min (Method A).

Level 9:

Preparation of {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -phenyl} -methanol:

To a solution, kept under nitrogen, of 9.5 g (27.5 mmol) of 3- [5- (2-

Morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzoic acid methyl ester in 180 ml

THF is added dropwise with stirring to 138 ml of a 1 M solution of diisobutylaluminum hydride in THF. After stirring for 1 hour at room temperature, 100 ml of a saturated aqueous ammonium chloride solution are added dropwise. The resulting precipitate is filtered off with suction and washed several times with dichloromethane. The filtrate is dried over sodium sulfate and evaporated. The residue is recrystallised from a mixture of isopropanol / ether: {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -phenyl} -methanol as yellow crystals; F. 101-102 °; ESI 316 (M + H); HPLC: Rt. = 1.67 min (Method A).

Step 10: Preparation of 4- {2- [2- (3-chloromethyl-phenyl) -pyrimidin-5-yloxy] -ethyl} -morpholine hydrochloride:

1 g (3.17 mmol) of {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -phenyl} -methanol are treated with 6 ml of thionyl chloride and stirred for 30 min at room temperature. The thionyl chloride was distilled off, coevaporated 3 times with toluene and further reacted directly without further purification: 4- {2- [2- (3-

Chloromethyl-phenyl) -pyrimidin-5-yloxy] -ethyl} -morpholine hydrochloride; pale yellow crystals, mp 183-184 °, HPLC: Rt. = 2.18 min (method A)

Stage 11: Preparation of 3- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl} -5-trifluoromethyl-3H-benzothiazol-2-one ("Al"):

A suspension of 89 mg (0.405 mmol) of 5-trifluoromethyl-3H-benzothiazol-2-one, 150 mg (0.405 mmol) of 4- {2- [2- (3-chloromethyl-phenyl) -pyrimidin-5-yloxy] - ethyl} -morpholine hydrochloride and 286 mg (2.02 mmol) of potassium carbonate in 8 ml of acetonitrile are stirred at 70 ^° C. for 5 days. The reaction mixture is mixed with 30 ml of water, which slowly forms a precipitate. The precipitate is filtered off with suction, washed with water and dried.

Product: ESI: 517 (M + H); Rt. = 2.72 min (Method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 8.64 (s, 2H), 8.28 (s, 1H), 8.22 (d, J = 7.8, 1H), 7.96 (d, J = 8.2 , 1 H), 7.69 (s, 1H), 7.56 (d, J = 8.2, 1H), 7.49 (t, J = 5.7.7, 1H), 7.42 (d, J = 7.6, 1H), 5.40 ( s, 2H), 4.30 (t, J = 5.6, 2H), 3.61 - 3.53 (m, 4H), 2.73 (t, J = 5.6, 2H), 2.49 (m, superimposed, 4H).

Analogously, the following compounds are obtained: 0

5-Chloro-3- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl} -3H-benzothiazol-2-one ("A2")

0 ESI: 483 (M + H); Rt. = 2.65 min (Method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 8.65 (s, 2H), 8.25 (s, 1H), 8.22 (d, J = 7.9, 1H), 7.74 (d, J = 8.4 , 1H), 7.49 (dd, J = 4.8, 10.3, 2H), 7.41 (d, J = 7.7, 1H), 7.26 (dd, J = 1.9, 8.4, 1H), 5.31 (s, 2H), 4.30 (t, J = 5.6,

2H), 3.63 - 3.50 (m, 4H), 2.73 (t, J = 5.6, 2H), 2.49 (m, superimposed, 4H) .5 6-Acetyl-3- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl} -3H-benzothiazol-2-one ("A3")

ESI: 505 (M + H); Rt. = 2.70 min (Method A);

¹ H NMR (500 MHz ₁ DMSO-d ₆ ) δ [ppm] 10.20 (b, 1H), 8.68 (s, 2H), 8.36 (d, J = 1.7, 1H), 8.23 (d, J = 9.2 , 2H), 7.93 (dd, J = 1.8, 8.6, 1H), 7.54 - 7.35 (m, 3H), 5.34 (s, 2H), 4.57 (s, 2H), 3.0-4.1 (m, 10H), 3.01 (q, J = 7.2, 2H), 1.07 (t, J = 7.2, 3H).

3- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl} -6-propionyl-3H-benzothiazol-2-one ("A3a")

5-Bromo-3- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl} -3H-benzothiazol-2-one ("A4")

ESI: 527/529 (M + H), Rt. = 2.79 min (Method A); ¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 10.05 (b, 1H), 8.70 (s, 2H), 8.24 (d, J = 6.3, 2H), 7.69 (d, J = 8.4, 1 H), 7.59 (d, J = 1.8, 1H), 7.49-7.55 (m, 1H), 7.45 (d, J = 7.6, 1H), 7.40 (dd, J = 1.9, 8.4, 1 H ) ₁ 5.32 (s, 2H), 4.57 (b, 2H), 2.99-3.99 (m, 1OH).

Preparation of 3- {3- [5- (3-dimethylamino-propoxy) -pyrimidin-2-yl] -benzyl} -5-trifluoromethyl-3H-benzothiazol-2-one ("A5"):

A suspension of 114 mg (0.52 mmol) of 5-trifluoromethyl-3H-benzothiazol-2-one, 150 mg (0.52 mmol) of {3- [5- (3-dimethylamino-propoxy) -pyrimidin-2-yl] - phenyl} -methanol and 261 mg (0.78 mmol) of polymer-bound triphenylphosphine (3 mmol / g) are shaken for 30 minutes at room temperature. 178 mg (0.78 mmol) of di-tert-butylazodicarboxylate are added to the suspension and, after stirring for 24 h at room temperature, 50 mg (0.15 mmol) of polymer-bound triphenylphosphine (3 mmol / g) and 35 mg (0.15 mmol) of diisocyanate are again -terf-butylazodicarboxylate and shaken for 2 h at room temperature. The reaction mixture is filtered, the filtrate is evaporated to dryness and the residue is purified by preparative HPLC. The product is present as trifluoroacetate; ESI: 489 (M + H); Rt. = 2.81 min (Method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 9.43 (s, 1H), 8.64 (s, 2H), 8.27 (s, 1H), 8.23 (d, J = 7.7, 1H) , 7.97 (d, J = 8.2, 1 H), 7.69 (s, 1 H), 7.56 (d, J = 8.2, 1 H), 7.50 (t, J = 7.7, 1 H), 7.45 (d, J = 7.7, 1H), 5.40 (s, 2H), 4.27 (t, J = 6.0, 2H), 3.24 (s, 2H), 2.83 (d, J = 3.4, 6H), 2.22 - 2.10 (m, 2H ). Analogously, the following compounds are obtained

3- {3- [5- (1-Methyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl] -benzyl} -5-trifluoromethyl-3H-benzothiazol-2-one ("A6")

ESI: 515 (M + H); Rt. = 2.92 min (Method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 8.62 (s, 2H), 8.28 (s, 1H), 8.22 (d, J = 7.8, 1H), 7.96 (d, J = 8.2 , 1 H), 7.69 (s, 1 H), 7.55 (d, J = 8.2, 1 H), 7.48 (t, J = 7.7, 1 H), 7.42 (d, J = 7.6, 1 H), 5.40 (s, 2H), 4.05 (d, J = 6.0, 2H) ₁ 2.84 (d, J = 11.2, 2H), 2.21 (s, 3H), 1.97 (s, 2H), 1.76 (d, J = 9.6, 3H), 1.43 - 1.27 (m, 2H).

3- {3- [5- (1-tert-Butoxycarbonyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl] -benzyl} -5-trifluoromethyl-3H-benzothiazol-2-one ("A7")

ESI: 545 (M - tert.butyl + H); Rt. = 3.95 min (method A).

Preparation of 3- {3- [5- (piperidin-4-ylmethoxy) pyrimidin-2-yl] benzyl} -5-trifluoromethyl-3H-benzothiazol-2-one ("A8")

424 mg (0.64 mmol) of 3- {3- [5- (1-tert-butoxycarbonyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl] -benzyl} -5-trifluoromethyl-3H-benzothiazol-2-one is dissolved in 20 ml of dioxane and treated with 6 ml of 4N HCl in dioxane. It is stirred for 24 h at room temperature. This forms a tough precipitate, which is filtered off with suction and stirred with isopropanol.

ESI: 501 (M + H); Rt. = 2.87 min (method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 8.92 (s, 1H), 8.65 (d, J = 15.2, 3H), 8.26 (s, 1H), 8.22 (d, J = 7.8 , 1 H) ₁ 7.96 (d, J = 8.2, 1 H), 7.67 (s, 1 H) ₁ 7.56 (d, J = 8.2, 1 H) ₁ 7.50 (t, J = 7.7, 1H), 7.43 ( d, J = 7.7, 1H) ₁ 5.39 (s, 2H) ₁ 4.09 (d, J = 6.4, 2H), 3.30 (d, J = 12.5, 2H) ₁ 2.90 (d, J = 10.8, 2H), 2.12 (s, 1 H) ₁ 1.93 (d, J = 12.3, 2H), 1.52 (d, J = 10.4, 2H).

Preparation of 3- [3- (5-Bromo-pyrimidin-2-yl) -benzyl] -5-trifluoromethyl-3H-benzothiazol-2-one ("A9a"):

Stage a:

Preparation of [3- (5-bromopyrimidin-2-yl) -phenyl] -methanol:

A solution of 6.11 g (21.5 mmol) of 5-bromo-2-iodopyrimidine, 3.91 g (25.7 mmol) of 3- (hydroxymethyl) -benzeneboronic acid and 9.11 g (42.9 mmol) of tripotassium phosphate trihydrate in 120 ml of dioxane and 14 ml Water is treated with 750 mg (0.65 mmol) of tetrakis (triphenylphosphine) palladium and stirred at 90 ° C for 18 hours. The reaction mixture is cooled to room temperature, treated with te / i-butyl methyl ether and water and filtered through kieselguhr. The organic phase of the filtrate is separated, dried over sodium sulfate and evaporated. The residue is chromatographed on a silica gel column with dichloromethane / methanol as eluent; Product: 2.49 g;

F. 114-117 °; ESI: 265, 267 (M + H); HPLC: Rt. = 2.51 min (Method A).

Stage b:

Preparation of 5-bromo-2- (3-chloromethyl-phenyl) -pyrimidine:

80 g (302 mmol) of [3- (5-bromopyrimidin-2-yl) -phenyl] -rnethanol are suspended in 300 ml of dichloromethane and, while cooling, 33 ml (453 mmol) of thionyl chloride are added slowly. The reaction mixture is added for 3 h Room temperature stirred. The solvent is distilled off, coevaporated 3 times with toluene and stirred with diethyl ether; pale yellow crystals, mp 146-148 °; HPLC: Rt. = 3.15 min (method A).

Stage c:

Preparation of 3- [3- (5-Bromo-pyrimidin-2-yl) -benzyl] -5-trifluoromethyl-3H-benzothiazol-2-one:

1 g (4.56 mmol) of 5-trifluoromethyl-3H-benzothiazol-2-one, 1.3 g (4.56 mmol) of 5-bromo-2- (3-chloromethyl-phenyl) -pyrimidine and 4.5 g (13.69 mmol) of cesium carbonate are dissolved in 15 ml of DMF and stirred for 15 h at room temperature and for 3 h at 80 ° C. The suspension is added to water and the precipitate is filtered off with suction, washed with methanol and dried in vacuo.

Beige crystals are obtained; HPLC: Rt. = 3.72 min (Method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 9.08 (s, 2H), 8.35 (s, 1H), 8.29 (d, J = 6.9, 1H), 7.98 (d, J = 8.2, 1H), 7.72 (s, 1H), 7.47-7.63 (m, 3H), 5.43 (s, 2H).

Preparation of 3- (3- {5- [1- (2-pyrrolidin-1-yl-ethyl) -1H-pyrazol-4-yl] -pyrimidin-2-yl} -benzyl) -5-trifluoromethyl-3H benzothiazol-2-one ("A9")

A solution, maintained under nitrogen, of 233 mg (0.50 mmol) of 3- [3- (5-bromo-pyrimidin-2-yl) -benzyl] -5-trifluoromethyl-3H-benzothiazol-2-one and 229 mg (1.10 mmol). 1- (2-Pyrrolidin-1-yl-ethyl) -4- (4,4,5,5-tetramethyl- [1,2,2] di-oxaborolan-2-yl) -1H-pyrazoline in 10 ml 1,2-Dimethoxyethane is combined with 212 mg (1.0 mmol) of tripotassium phosphate trihydrate and 28 mg (0.04 mmol) of bis (tris-phenylphosphine) -palladium chloride and stirred at 80 ° C. for 18 hours. 28 mg (0.04 mmol) of bis (triphenylphosphine) -palladium chloride are added twice more, and the mixture is stirred at 80 ° C. for 24 hours. The reaction mixture is diluted with water, extracted with ethyl acetate, dried and evaporated. The crude product is purified by column chromatography on silica gel (dichloromethane / methanol).

ESI: 550 (M + H); HPLC: 2.70 min (Method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 9.17 (s, 2H), 8.50 (s, 1H) ₁ 8.43 (s, 1H), 8.38 (d, J = 7.0, 1H) , 8.23 (s, 1H), 7.93 (d, J = 8.1, 1 H), 7.70 (s, 1 H), 7.47-7.59 (m, 3H), 5.45 (s, 2H), 4.62 (t, J = 6.0, 2H), 3.77 (t, J = 6.1, 2H), 3.68 - 3.55 (m, 2H), 3.16 - 3.03 (m, 2H), 2.11 - 1.99 (m, 2H), 1.98 - 1.83 (m, 2H ).

Preparation of 5- (1-methyl-1H-pyrazol-4-yl) -3- {3- [5- (2-morpholinyl-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl} -3H benzothiazol-2-one ("A10"):

A solution of 122 mg (0.15 mmol) of 5-bromo-3- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl} -3H-benzothiazole, kept under nitrogen. 2-one and 35 mg (0.15 mmol) of i-methyl-W-Aδ.S-tetramethylH.sub.1-iodobenzaborolan-2-yl) -1H-pyrazole in 4 ml of 1,2-dimethoxyethane is treated with 65 mg (0.30 mmol). Tripotassium phosphate trihydrate and 9 mg (0.01 mmol) of bis (triphenylphosphine) - palladium chloride added and stirred at 80 ° C for 18 hours. 9 mg (0.01 mmol) of bis (triphenylphosphine) -palladium chloride are added twice more and the mixture is stirred at 80 ° C. for 24 hours. The reaction mixture is diluted with water, extracted with ethyl acetate, dried and evaporated. The crude product is purified by preparative HPLC. The product is present as trifluoroacetate.

ESI: 529 (M + H); HPLC: 2.32 min (Method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 9.95 (b, 1H), 8.69 (s, 2H), 8.30 (s, 1H), 8.22 (d, J = 7.3, 1H) , 8.14 (s, 1H), 7.88 (s, 1H), 7.64 (d, J = 8.2, 1H), 7.57 (d, J = 1.4, 1 H) ₁ 7.55 - 7.45 (m, J = 1.6, 8.2, 2H), 7.40 (dd, 1H), 5.34 (S ₁ 2H), 4.56 (s, 2H), 2.99-3.99 (m, 10H), 3.84 (s, 3H).

Preparation of 3- {3- [5- (4-Methyl-piperazin-1-yl) -pyrimidin-2-yl] -benzyl} -5-trifluoromethyl-3H-benzothiazol-2-one ("A11"):

Stage a:

933 mg (2 mmol) of 3- [3- (5-bromo-pyrimidin-2-yl) -benzyl] -5-trifluoromethyl-3H-benzothiazol-2-one are suspended in 10 ml of dioxane and treated with 660 mg (4.4 mmol ) Sodium iodide and 19 mg (0.1 mmol) of copper (I) iodide were added. There were added 35 ul (0.22 mmol) of trans-Λ /, Λ / -dimethyl-1, 2-cyclohexandiamin and refluxed under argon for 48h. An additional 35 μl (0.22 mmol) of trans-Λ /, Λ / -dimethyl-1,2-cyclohexanediamine and 19 mg (0.1 mmol) of copper (I) iodide are added and the reaction mixture is refluxed for 3 days.

The reaction mixture is stirred into water, the precipitate is filtered off with suction and the residue is dried in vacuo.

ESI: 514 (M + H); HPLC: 3.72 min (Method A).

Stage b:

513 mg (1 mmol) of 3- [3- (5-iodo-pyrimidin-2-yl) benzyl] -5-trifluoromethyl-3H-benzothiazol-2-one is suspended in toluene, heated briefly to 100 ⁰ C and Room temperature cooled. Subsequently, 134 .mu.l (1.2 mmol) of methylpiperazine, 297 mg (1.4 mmol) of potassium phosphate trihydrate, and 33 mg (0.08 mmol) 2-dicyclohexylphosphino-2 ^{', 6'} -dimethoxybiphenyl and 18 mg (0:02 mmol) of tris (benzylidenacetone) are added dipalladium and under argon atmosphere at 100 ⁰ C stirred. 33 mg once (0.08 mmol) 2-dicyclohexylphosphino-2 ^{', 6'} -dimethoxybiphenyl and 18 mg (0:02 mmol) of tris (dibenzylideneacetone) dipalladium were added and then stirred for a further 24 h under an argon atmosphere at 100 ⁰ C. The reaction mixture is mixed with water, extracted with ethyl acetate and dried. The crude product is purified by preparative HPLC. The product is present as trifluoroacetate.

ESI: 486 (M + H); HPLC: 2.53 min (Method A);

¹ H NMR (500 MHz ₁ DMSO-d ₆ ) δ [ppm] 8.58 (s, 2H), 8.24 (s, 1H), 8.19 (d, J

= 7.9, 1 H), 7.98 (d, J = 8.2, 1H), 7.69 (s, 1 H), 7.57 (d, J = 8.2, 1 H), 7.46 (t, J = 7.7, 1H), 7.38 (d, J = 7.7, 1H), 5.40 (s, 2H) ₁ 3.3 and 2.5 (superimposed, 8H) 2.27 (S ₁ 3H).

Preparation of 5-chloro-3- [3- (5-methyl- [1,2,4] oxadiazol-3-yl) benzyl] -3H-benzothiazol-2-one ("A12")

Stage a:

Stage b:

Stage a:

50.9 g (233 mmol) of methyl 3- (5-methyl- [1,2,4] oxadiazol-3-yl) benzoate are dissolved in 500 ml of THF and treated with stirring at ⁰ ° C. in portions with 5.6 g (256 mmol ) Lithium borohydride. The reaction mixture is stirred at room temperature for 20 h and then a pH of 7 is adjusted with 1 N HCl. It is diluted with 500 ml of water and extracted with 3 x 500 ml of dichloromethane. The combined organic phases are washed with water, dried and purified by column chromatography on silica gel. ESI: 191 (M + H); F. 42 °.

Stage b: 9.83 g (51.7 mmol) of [3- (5-methyl- [1,2,4] oxadiazol-3-yl) -phenyl] -methanol are dissolved in 150 ml of toluene; heated to 35 ° C and then 4.91 mol (52 mmol) of phosphorus tribromide, dissolved in toluene, added dropwise. The mixture is stirred for 1 h at 35 ° C and 2 h at RT. The batch is stirred into ice-water. It is extracted three times with ethyl acetate. The organic phase is dried and concentrated. The crude product is purified by column chromatography on silica gel (PE / EA, 9: 1).

This gives white crystals, mp 64 °, ESI: 254 (M + H).

Stage c:

A suspension of 100 mg (0.54 mmol) of 5-chloro-3H-benzothiazol-2-one, 153 mg (0.59 mmol) of S, S-bromo-methyl-phenyl-δ-methyl-tert-1-yoxadiazole and 303 mg (2.16 mmol). Potassium carbonate in 20 ml of acetonitrile are stirred at 80 ^° C. for 1 h. The reaction mixture is mixed with 30 ml of water, extracted with MTBE, dried and evaporated to dryness. The crude product is purified by column chromatography on silica gel and stirred with ether.

One obtains "A12": ESI: 358 (M + H); Rt. = 3.25 min (method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] 7.97 (s, 1H), 7.93 (d, J = 7.6, 1H), 7.75 (d, J = 8.4, 1H), 7.57 ( t, J = 7.6, 1H), 7.52 (m, 2H), 7.28 (dd, J = 2.0, 8.4, 1H), 5.33 (s, 2H), 2.66 (s, 3H).

Preparation of [3- (5-chloro-2-oxo-benzothiazol-3-ylmethyl) -phenyl] -carbamic acid 3- (4-methylpiperazin-1-yl) -propyl ester ("A13"):

Stage c:

Stage a:

4.5 g (12.8 mol) of 5-chloro-3- (3-nitrobenzyl) -3H-benzothiazo-2-one ["A13a"; prepared analogously to "A12"; ESI: 321 (M + H); Rt. = 3.20 min (method A)] are dissolved in 100 ml of THF and hydrogenated with 2 g of palladium on activated carbon (water-wet, 5% Pd) under a hydrogen atmosphere at room temperature. After 24 hours, the catalyst is filtered off with suction, washed with THF and evaporated. There is obtained 3- (3-aminobenzyl) -5-chloro-3H-benzothiazol-2-one, ESI: 291 (M + H); HPLC: Rt. = 2.28 min (Method A).

Stage b:

4.775 g (30 mmol) of 3- (4-methyl-piperazin-1-yl) -propan-1-ol are dissolved in 20 ml of dioxane, mixed with 20 ml of 4N HCl in dioxane and concentrated to dryness. This residue is triturated in MTBE, filtered off with suction and dried. This solid (6.7 g) is suspended in 50 ml of acetonitrile and treated at 0 ° with 6 g (30 mmol) Trichloromethychoroforrniat dissolved in 10 ml of acetonitrile. It is stirred for a further 48 h at room temperature. The reaction mixture is filtered off with suction, washed with acetonitrile and dried. This gives a white solid, mp 248-250 ° (decomposition). Stage c:

173 mg (0.36 mmol) of 3- (3-aminobenzyl) -5-chloro-3H-benzothiazol-2-one and 198 mg (0.67 mmol) of 3- (4-methylpiperazin-1-yl) -propane 1-chloroformate are suspended in 3 ml of THF and treated with 253 .mu.l (1.46 mmol) of DIPEA. The reaction mixture is stirred overnight at room temperature. The suspension is mixed with 50 ml of dichloromethane and then washed with 10 ml of 2N NaOH, dried and evaporated. The crude product is purified by preparative HPLC.

The product "A13" is present as trifluoroacetate.

ESI: 475 (M + H); HPLC: Rt. = 2.43 min (Method A);

¹ H NMR (500 MHz, DMSO-d ₆ ) δ [ppm] δ 9.61 (s, 1H), 9.48-8.86 (b, 1H), 7.74 (d, J = 8.4, 1H), 7.39 (i.e. , J = 8.1, 1H), 7.34 (s, 2H), 7.23-7.30 (m, 2H), 6.97 (d, J = 7.5, 1H), 5.16 (s, 2H), 4.09 (m, 2H) , 2.45-3.50 (superimposed, 13H), 1.81 (b, 2H).

Reaction of 3- (3-aminobenzyl) -5-chloro-3H-benzothiazol-2-one with ethyl formate gives [3- (5-chloro-2-oxo-benzothiazol-3-ylmethyl) -phenyl] - Carbamic acid ethyl ester ("A14")

Analogous to the above-mentioned rules, the following compounds are obtained

"A15":

ESI: 550 (M + H);

"A16":

ESI: 561 (M + H).

Pharmacological data

Met kinase inhibition (enzyme assay) Table 1

1OnM-1 μM = A 1 μM-10 μM = B> 10 μM = C

The following examples relate to drugs:

Example A: Injection glasses

A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 l of twice-distilled water with 2N hydrochloric acid, filtered sterile, filled into injection jars, lyophilized under sterile conditions and closed under sterile conditions , Each injection jar contains 5 mg of active ingredient.

Example B: Suppositories

A mixture of 20 g of an active compound of the formula I is melted with 100 g of soya lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool.

Each suppository contains 20 mg of active ingredient.

Example C: Solution

A solution of 1 g of an active compound of the formula I, 9.38 g of NaH ₂ PO ₄ • 2H ₂ O, 28.48 g of Na ₂ HPO ₄ • 12H ₂ O and 0.1 g of benzalkonium chloride in 940 is prepared ml of double distilled water. Adjust to pH 6.8, make up to 1 liter and sterilize by irradiation. This solution can be used in the form of eye drops.

Example D: Ointment

500 mg of an active compound of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions. Example E: Tablets

A mixture of 1 kg of active ingredient of the formula I ₁ 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate in the usual manner

Tablets compressed so that each tablet contains 10 mg of active ingredient.

Example F: dragees

Tablets are pressed analogously to Example E, which are then coated in the usual way with a coating of sucrose, potato starch, talc, tragacanth and dye.

Example G: Capsules

2 kg of active compound of the formula I are filled in the usual way in hard gelatin capsules, so that each capsule contains 20 mg of the active ingredient.

Example H: Ampoules

A solution of 1 kg of active compound of the formula I in 60 l of bidistilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each vial contains 10 mg of active ingredient.

Claims

claims

1. Compounds of the formula I

wherein

E, E ¹ , E ", E" ¹ each independently of one another C or N,

R ¹ , R ^{2 are} each independently H or A, 5 R ¹ and R ² together also (CH ₂ ) _P , where 1 or 2 CH ₂ group (s) may be replaced by O and / or NH, R ³ H , Ar, (CH ₂ ) nCONH ₂ , (CH ₂ ) _n CONHA, (CH ₂ ) _H CONAA ¹ , A,

COA, OH, OA, CONH (CH ₂₎ m NH _2, CONH (CH ₂₎ MNHA, _o CONH (CH _{2) m} NAA \ CO (CH _{2) m} NH _2, CO (CH _{2) m} NHA,

CO (CH _{2) O1} NAA ^1, CO (CH _{2) m} Het, CH (OH) A, CN, (CH _{2) n} Het _(Hal, CONH (CH _{2) m} NA-COOA, SO ₂ A, NH ( CH ₂ ) _m NH ₂ , NH (CH ₂ ) _m NHA, NH (CH ₂ ) _m NAA ', (CH ₂ ) _n COOH, (CH ₂ ) _n COOA, O (CH ₂ ) _m NH _2lO (CH ₂ ) _m NHA, O (CH ₂ ) _m NAA ', ⁵ OHet, N = CH-NAA ¹ , N = CH-NHA, N = CH-NH ₂ ,

O (CH ₂ ) _m Het, N (R ⁶ ) ₂₎ NR ⁶ COA, NR ⁶ SO ₂ A, SO ₂ N (R ⁶ J ₂ , [C (R ⁶ ) ₂ ] _n N (R ⁶ ) _2l S [C (R ⁶ ) ₂ ] jpN (R ⁶ ) ₂ , S [C (R ⁶ ) ₂ ] _n Het, -NR ⁶ [C (R ⁶ ) ₂ ] _n Het, NHCON (R ⁶ ) ₂₎ NHCONH [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂ , 0 NHCONH [C (R ⁶ ) ₂ ] _n Het, NHCO [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂₎

NHCO [C (R ⁶ ) ₂ ] _n Het, CONR ⁶ [C (R ⁶ ) ₂ ] _n Het, COHet, O [C (R ⁶ ) ₂ ] _P NR ⁶ COZ, O [C (R ⁶ ) ₂ ] _p NR ² COHet ¹ , O [C (R ⁶ ) ₂ ] _n Cyc [C (R ⁶ ) ₂ ] _n OR ⁶ , O [C (R ⁶ ) ₂ ] _n Cyc [C (R ⁶ ) ₂ ] _n Het ¹ , 5 CH ₂ - (CH ₂ ),

\ / O [C (R ⁶ ) ₂ ] _n -C- [C (R ⁶ ) ₂ ] _n N (R ⁶ ) _{2 f}

CH ₂ - (CH ₂ ) _q /

O [C (R ⁶ ) ₂ ] _n -C- [C (R ⁶ ) ₂ ] _n OR ⁶ ,

CH ₂ - (CH ₂ ),

\ /

O [C (R ⁶ ) ₂ ] _n -C- [C (R ⁶ ) ₂ ] _n Het ₇

O [C (R ⁶ ) ₂ ] n CR ⁶ (NR ⁶ ) ₂ COOR ⁶ ,

O [C (R ⁶ ) ₂ ] n NR ⁶ CO [C (R ⁶ ) ₂ ] n NR ⁶ COA, O [C (R ⁶ ) ₂ ] _P NR ⁶ COOA,

O [C (R ⁶ ) ₂ ] n CO-NR ⁶ - [C (R ⁶ ) ₂ ] n Het ¹ , O [C (R ⁶ ) ₂ ] n CONH ₂ , O [C (R ⁶ ) ₂ ] _n CONHA, O [C (R ⁶ ) ₂ ] _n CONA ₂ ,

O [C (R ⁶ ) ₂ ] n CO-NR ⁶ - [C (R ² ) ₂ ] _n N (R ⁶ ) ₂ or OCOA ₁ Z CR ⁶ (NR ⁶ ) ₂ CR ⁶ (OR ⁶ ) A,

R ^{3 'is} H or Hal, R ^{4 is} Het ¹ , NHCOOR ⁵ , NHCONHR ⁵ , NHCOCONHR ⁵ , NO ₂ or

NHCOA,

R ^{4 'is} H or Hal,

R ⁴ and R ^{4 '} together also NHCONH, R ⁵ A, (CH ₂ ) _m NH ₂ , (CH ₂ ) _m NHA, (CHz) _1n NAA ¹ or (CH ₂ ) _m Het,

Ar is unsubstituted or mono-, di- or trisubstituted by Hal,

A, OH, OA, N (R ⁶ ) ₂ , SR ⁶ , NO ₂ , CN, COOR ⁶ , CON (R ⁶ ) ₂ ,

NR ⁶ COA, NR ⁶ SO ₂ A, SO ₂ N (R ⁶ ) _2> S (O) _n A CO-Het ¹ ,

[C (R ⁶ ) ₂ ] _n N (R ⁶ ) ₂ , [C (R ⁶ ) ₂ ] _n Het ¹ , O [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂ ,

O [C (R ⁶ ) ₂ ] _n Het ¹ , NHCOOA, NHCON (R ⁶ ) ₂ ,

NHCOO [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂ , NHCOO [C (R ⁶ ) ₂ ] _n Het ¹ , NHCONH [C (R ⁶ ) ₂ ] _P N (R ³ ) ₂ , NHCONH [C (R ⁶ ) ₂ ] _n Het ¹ , OCONH [C (R ⁶ ) ₂ ] _P N (R ⁶ ) ₂ and / or OCONH [C (R ⁶ ) ₂ ] _n Het ¹ substituted phenyl, naphthyl or biphenyl, Het a mono- or binuclear saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR ⁶ , N (R ⁶ ) ₂ , NO ₂ , CN, COOR ⁶ , CON (R ⁶ ) ₂ , NR ³ COA, NR ⁶ SO ₂ A, SO ₂ N (R ⁶ ) ₂ ,

S (O) _n A NHCOOA, NHCON (R ⁶ ) ₂ , CHO, COA, = S, = NH, = NA and / or = 0 (carbonyl oxygen) may be substituted, Het ^{1 is} a mononuclear aromatic heterocycle having 1 to 4

N, O and / or S atoms which is unsubstituted or mono-, di- or trisubstituted, each independently of one another, may be substituted by R ³ , R ^{6 is} H or A,

A, A ^{1 are} each independently of one another unbranched or branched alkyl having 1-10 C atoms, wherein 1-7 H atoms may be replaced by F, Cl and / or Br, and / or wherein one or two CH ₂ groups

O, S, SO, SO ₂ and / or CH = CH groups may be replaced, or cyclic alkyl having 3-7 C atoms,

Cyc cycloalkylene having 3-7 C atoms,

Hal is F, Cl, Br or I, m is 1, 2, 3 or 4, n is O, 1, 2, 3 or 4, p is 1, 2, 3, 4 or 5, q is 1, 2, 3, 4 or 5 and their pharmaceutically acceptable salts, tautomers and

Stereoisomers, including mixtures thereof in all ratios.

2. Compounds according to claim 1, wherein

A, A ¹ each independently represent unbranched or branched alkyl having 1-10 C atoms, wherein 1-7 H atoms may be replaced by F and / or Cl, as well as their pharmaceutically acceptable salts, tautomers and stereoisomers, including their Mixtures in all proportions. 10

3. Compounds according to one or more of claims 1-2, wherein Het a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 3 N, O and / or S

Atoms which is unsubstituted or may be monosubstituted or disubstituted by A and / or COOR ⁶ , and their pharmaceutically acceptable salts, tautomers and

Stereoisomers, including mixtures thereof in all ratios. 20

4. Compounds according to one or more of claims 1-3, wherein Het piperidinyl, pyrrolidin-yl, morpholin-4-yl, piperazin-yl, 1, 3

Oxazolidin-3-yl, imidazolidinyl, oxazolyl, oxadiazolyl, thiazolyl 25, thienyl, furanyl or pyridyl, wherein the radicals also once or twice by A and / or

COOR ⁶ , and their pharmaceutically acceptable salts, tautomers and

Stereoisomers, including mixtures thereof in all ratios.

5. Compounds according to one or more of claims 1-4, wherein

E, E ¹ , E ", E ¹ " denote C,

35 and their pharmaceutically acceptable salts, tautomers and

Stereoisomers, including mixtures thereof in all ratios.

6. Compounds according to one or more of claims 1-5, wherein R ¹ , R ^{2 is} H, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions.

7. Compounds according to one or more of claims 1-6, wherein R ^{3 is} A, COA ₁ (CH ₂ ) _n Het, Hal, O (CH ₂ ) _m NAA 'or O (CH ₂ ) _m Het, and their pharmaceutically usable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.

8. Compounds according to one or more of claims 1-7, wherein R ^{3 'is} H, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions.

9. Compounds according to one or more of claims 1-8, wherein

R ^{4 is} Het ¹ , NHCOOR ⁵ or NO ₂ , as well as their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.

10. Compounds according to one or more of claims 1-9, wherein R ^{4 'is} H, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions.

11. Compounds according to one or more of claims 1-10, wherein R ^{5 is} (CH ₂ ) _m Het, and their pharmaceutically acceptable salts, tautomers and

Stereoisomers, including mixtures thereof in all ratios.

12. Compounds according to one or more of claims 1-11, wherein R ^{6 is} H, methyl, ethyl, propyl, isopropyl, butyl or tert-butyl, and their pharmaceutically acceptable salts, tautomers and

Stereoisomers, including mixtures thereof in all ratios.

13. Compounds according to one or more of claims 1-12, wherein Het ¹ 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1 -0, 2, 4- or 5 -imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4 or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazoM-, -A- or -5-yl, ₅ 1, 2,4-triazole-1 -, -3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-

Oxadiazol-4 or -5-yl, 1, 2,4-oxadiazol-3 or -5-yl, 1, 3,4-thiadiazol-2 or -5-yl, 1, 2,4-thiadiazole 3- or -5-yl, 1, 2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl or pyrazinyl, which is unsubstituted or mono- or disubstituted by A ⁰ ₁ O (CH _{2) m} NH ₂ , O (CH ₂ ) _m NHA, O (CH ₂ ) _m NAA ', Het,

OHet, N = CH-NAA ¹ ,

N = CH-NHA, N = CH-NH ₂ and / or O (CH ₂ ) _m Het, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios. Q

14. Compounds according to one or more of claims 1-13, wherein E, E ¹ , E ", E" ¹ C,

R ¹ , R ² H,

R ³ A, COA, (CH ₂ ) _n Het, Hal, O (CH ₂ ) _m NAA 'or O (CH ₂ ) _m Het,

R 3 ¹ H, 5

R ^{4 is} Het ¹ , NHCOOR ⁵ or NO ₂ ,

R ^{4 '} H, R ⁵ (CH ₂ ) _m Het,

Ar mono-, di- or trisubstituted by Hal and / or CN substituted phenyl,

Het piperidinyl, pyrrolidin-yl, morpholin-4-yl, piperazin-yl, 1, 3

Oxazolidin-3-yl, imidazolidinyl, oxazolyl, oxadiazolyl, thiazolyl, thienyl, furanyl or pyridyl, where the radicals can also be mono- or disubstituted by A and / or COOR ⁶ , Het ¹ 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl,

1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazoM-, -4- or -5-yl,

1, 2,4-triazole-1, 3 or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or 5-yl, 1, 2,4-oxadiazole 3- or -5-yl, 1,3,4-thiadiazol-2 or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1, 2,3-thiadiazole-4 or -5-yl, 3- or 4-pyridazinyl or pyrazinyl which is unsubstituted or mono- or disubstituted by A ₁ O (CH ₂ ) _m NH ₂ , O (CH ₂ ) _m NHA, O (CH ₂ ) _m NAA Het,

OHet, N = CH-NAA ¹ ,

N = CH-NHA, N = CH-NH ₂ and / or O (CH ₂ ) _m Het are substituted,

R ^{6 is} H, methyl, ethyl, propyl, isopropyl, butyl or tert-butyl,

A, A ^{1 in} each case independently of one another are unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and / or Cl,

Hal is F, Cl, Br or I, m is 1, 2, 3 or 4, and their pharmaceutically acceptable salts, tautomers and

Stereoisomers, including mixtures thereof in all ratios.

15. Compounds according to claim 1, selected from the group

and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.

16. A process for the preparation of compounds of the formula I according to claims 1-15 and their pharmaceutically acceptable salts, tautomers and stereoisomers, characterized in that

a) a compound of formula II

wherein E, E ¹ , E ", E ¹ ", R ³ and R ^{3 have} the meanings given in claim 1,

o with a compound of formula III

wherein R ¹ , R ² , R ⁴ and R ^{4 have} the meanings given in claim 1 and 0

L is Cl, Br, I or a free or reactive functionally modified OH group,

5 and / or converts a base or acid of formula I into one of its salts. _Q 17. A medicament containing at least one compound of formula I according to claim 1-15 and / or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants. 5

18. Use of compounds according to claims 1-15 and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios, for the manufacture of a medicament for the treatment of diseases in which the inhibition, regulation and / or modulation of the

Signal transduction of kinases plays a role.

19. Use according to claim 18, for the manufacture of a medicament for the treatment of diseases which are influenced by inhibition of met kinase by the compounds according to claims 1-15.

Use according to claim 19, wherein the disease to be treated is a solid tumor.

21. Use according to claim 19, wherein the disease to be treated is a tumor of the blood and immune system.

22. Medicaments containing at least one compound of the formula I according to one or more of claims 1 to 15, and / or their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios, and at least one further active pharmaceutical ingredient.

23. Set (Kit) consisting of separate packs of

(A) an effective amount of a compound of formula I according to one or more of claims 1 to 15, and / or their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions, and

(b) an effective amount of another drug active.